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Abstract 
  
Lifestyle diseases like obesity and type 2 diabetes are highly prevalent worldwide, and represent 
a major public health concern. A potential link between lifestyle diseases and methylmercury 
exposure have been proposed in several studies. Methylmercury is an ubiquitous environmental 
contaminant emerging from both natural and anthropogenic sources. Methylmercury 
accumulates in the marine food chain and therefore represent a potential health risk for 
consumers. We aimed to investigate the potential role of methylmercury on obesity 
development and diabetes, evaluating dose response effects of methylmercury, and the effects 
on glucose tolerance and insulin sensitivity. In addition, we aimed to explore the accumulation 
of mercury in different tissues of the body. Obesity-prone C57BL/6 mice were exposed to an 
obesogenic high fat/high sucrose diet. Progressive concentrations of methylmercury-cysteine 
complex were added to the diets at 0.3 mg/kg, 1mg/kg, 3 mg/kg and 10 mg/kg. Our results 
demonstrated that chronic exposures to methylmercury did not induce obesity development: 
however, it attenuated obesity development and reduced basal insulin secretion due to the 
highest exposure (10 mg/kg). Further, we found a dose-dependent accumulation of mercury in 
several organs, with the highest levels accumulated in liver and pancreas.  
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1 Introduction 
1.1 Non-communicable diseases (NCD’s) 
The global burden of lifestyle diseases is alarming. According to the World Health Organization 
(WHO), non-communicable diseases (NCD’s), including cardiovascular disease, cancer, 
osteoporosis, chronic respiratory diseases, obesity and diabetes are currently the cause of 60% 
of all deaths (WHO, 2011). NCD’s are largely preventable through the reduction of behavioral 
risk factors like physical inactivity and unhealthy diets, subsequently affecting development 
and progression of obesity and type 2 diabetes. 
The increase in NCD’s has been largely attributed energy imbalance, however, emerging 
evidence claim a more holistic view on this endemic (Chen et al., 2009; Grandjean et al., 2011). 
Findings from methylmercury (MeHg) exposed populations have given indications of an 
association with type 2 diabetes (Eto, 1997). However, studies in humans are limited and often 
contradictory and many questions remains unanswered (He et al., 2013; Mozaffarian et al., 
2013). Still, both in-vitro studies and in-vivo studies using mouse models have linked MeHg to 
the development of type 2 diabetes (Chen et al., 2006b; Chen et al., 2006c). Given the 
tremendous burden of obesity and type 2 diabetes, clarifying the potential effects of MeHg 
would be a significant contribution to public health. 
1.1.1 Overweight and obesity 
Overweight and obesity are conditions of excessive fat accumulation that may have adverse 
effects on health (WHO, 2000). Overweight and obesity are commonly assessed using body 
mass index (BMI, kg/m2), due to its strong correlation to body fat content. BMI measures should 
be in the range of 18.5 to 24.9 kg/m2 for individuals to achieve optimal health. Obesity triggers 
adverse metabolic responses in blood pressure, triglycerides cholesterol, and insulin resistance 
thereby increasing the risk of coronary heart disease, ischemic stroke, type 2 diabetes mellitus 
etc. (WHO, 2011). Obesity is a complex disease that involves physiological, metabolic, social, 
cultural, educational, behavioral and genetic factors. Fundamentally, the development of 
overweight and obesity is caused by an imbalance between energy intake and expenditure 
(Bray, 2004). Modern society promotes an increase in energy consumption through a constant 
supply of cheap energy dense foods and persuasive food marketing (Lancet, 2011). 
Concomitantly, there is a reduction in physical activity due to a more sedentary environment, 
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ultimately leading to an excess of energy, which is stored as fat. This storage, through 
hyperplasia and/or hypertrophy of fat cells is essential in the pathology of obesity (Bray, 2004).  
White adipose tissue functions both as an energy storage and as an endocrine organ, and plays 
a pivotal role in the regulation of immune and inflammatory processes (Federico et al., 2010). 
The condition of obesity is characterized by low-grade systemic inflammation, caused by 
enlarged fat cells and the recruitment of macrophages. The secretion of adipokines, chemokines 
and cytokines (leptin, adiponectin, resistin, tumor necrosis factor alfa, interleukin etc.) from 
adipose tissue, have led to the discovery of several pathways linking adipose tissue metabolism 
and the immune system. Activation of the innate immune system, can in turn lead to impaired 
glucose tolerance, insulin resistance and type 2 diabetes. 
 
1.1.2 Diabetes 
The global obesity epidemic is accompanied by an increasing prevalence of type 2 diabetes 
(Kahn et al., 2014). Type 2 diabetes is characterized by elevated blood glucose and insulin 
resistance. Initially, insulin secretion increases but as the disease progresses, β-cell dysfunction 
and/or apoptosis occurs.  
Glucose homeostasis is orchestrated by a number of factors, insulin being key due to its anabolic 
qualities distributing glucose throughout insulin sensitive tissues of the body. Insulin is 
synthesized, packaged and secreted from pancreatic β-cells. In the endocrine islets of 
Langerhans, insulin secretory β-cells are surrounded by α-cells, secreting glucagon. Insulin and 
glucagon counteract in keeping blood sugar within a fairly narrow range.  
The regulation of blood glucose 
Food intake leads to an increase of glucose and amino acids in the circulation. Elevated glucose 
levels increase glucose uptake through glucose transporters (GLUT2) into β-cells of the 
pancreas (Layden et al., 2010). Glycolysis transforms glucose to pyruvate, and the majority is 
transported to the mitochondria.  The ATP/ADP ratio increase in line with glucose utilization 
through glycolysis, TCA cycle and oxidative phosphorylation (Rolo and Palmeira, 2006). This, 
in turn, stimulates ATP sensitive potassium (K+) channels to close, causing depolarization of 
the β-cells through voltage-sensitive calcium (Ca2+) channels (Layden et al., 2010). As the cells 
depolarize, membrane bound Ca2+ channels facilitate influx of Ca2+. This intracellular calcium 
accumulation triggers the exocytosis of insulin vesicles and thereby β-cell insulin secretion. 
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Changes in ATP/ADP caused by mitochondrial dysfunction influences glucose stimulated 
insulin secretion (Lowell and Shulman, 2005). 
The regulation of Ca2+ in pancreatic β-cells is mainly determined by the interplay between Ca2+ 
cell-entry, deposition of Ca2+ into intracellular compartments and elimination via microsomal 
Ca2+ pumps (Zhou et al., 1998). Inhibition of microsomal Ca2+ pumps causes depletion of 
intracellular calcium stores, which could increase intracellular free Ca2+. Inhibitory actions on 
the complexes of the mitochondrial respiratory chain have been found to inhibit insulin output 
from pancreatic β-cells. Although insulin secretion is regulated by a number of factors separate 
from this pathway, it is evident that oxidative phosphorylation is essential in glucose stimulated 
insulin secretion (MacDonald and Fahien, 1990). 
Insulin action 
Once into the bloodstream, insulin exerts its biologic effects on various insulin-sensitive tissues 
as illustrated in fig.1-1 (Saltiel and Kahn, 2001). Activation of multiple signaling pathways 
influences a number of key regulatory transcription factors involved in metabolic processes. 
Skeletal muscle and liver are pivotal insulin-responsive organs responsible for the balance of 
glucose metabolism (Lowell and Shulman, 2005). Transition towards an insulin-resistant state 
in these organs are accountable for most of the perturbations of glucose homeostasis, seen in 
type 2 diabetes. In muscle, insulin promotes glucose uptake and storage of glycogen. 
Approximately 90% of insulin stimulated glucose uptake occurs in skeletal muscle (Leto and 
Saltiel, 2012). Although the insulin stimulated uptake in adipose tissue is markedly lower than 
muscle (10%) it is essential in regulating energy homeostasis. Adipose tissue responds to insulin 
by increasing glucose uptake and lipogenesis, successively storing energy as triglycerides. 
Under obese conditions, adipose tissue releases free fatty acids into the circulation in an 
uncontrolled manner. The increase in circulatory fatty acids potentially inhibits glucose uptake, 
glycogen synthesis and glucose oxidation, and increase hepatic glucose secretion. In addition, 
circulating cytokines secreted by adipose tissue might modulate insulin-responsiveness of 
skeletal muscle and liver, in which fatty acids and intracellular fatty acid metabolites are 
suggested to play a major role.  
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Figure 1-1. Energy homeostasis is dependent upon the crosstalk of multiple organs and tissues. Collectively, these 
organs respond to energy demand and availability through the release of hormones and metabolites. Defects in 
the response and miscommunication result in metabolic diseases, such as diabetes (Leto and Saltiel, 2012). 
In the liver, insulin stimulates glycogen synthesis, lipogenesis and inhibits gluconeogenesis. 
Insulin inhibits several genes involved in gluconeogenesis, including Foxo1, Pck1, and G6pc 
(Saltiel and Kahn, 2001). In the presence of insulin, Forkhead box protein-1 (Foxo-1) indirectly 
hinders gluconeogenesis through inhibitory actions on the transcription of glucose-6-
phophatase (G6pc) and through the rate-limiting step, phosphoenolpyruvate carboxykinase 
(Pck1)(Quinn and Yeagley, 2005). Additionally, insulin influences the expression of 
transcription factors like sterol regulatory element-binding transcription factor (Srebp1), which 
stimulate gluconeogenesis and lipogenic genes such as Acetyl-CoA carboxylase (Acc1) and 
fatty acid synthase (Fas) (Saltiel and Kahn, 2001).  
In response to circulating insulin, glut 4 relocates to the cell membrane of fat and muscle to 
facilitate glucose entry into the cells (Leto and Saltiel, 2012). Insulin binds to its receptor 
(tyrosine kinase) at the cell surface, inducing phosphorylation of various insulin receptor 
substrates (IRS) (Leto and Saltiel, 2012). This family of adaptor proteins initiates the activation 
of other protein kinases and phosphatases, ultimately leading to insulin action. Metabolic 
processes are regulated through pathways that coordinate enzyme, activation/inactivation, 
protein synthesis, vesicle trafficking and gene expression. 
In summary, insulin excise its profound anabolic abilities by stimulating the metabolic 
processes of energy storage and simultaneously inhibiting the processes that release energy into 
the bloodstream. 
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Counter regulatory mechanisms 
Circulating glucose below a certain threshold stimulates counter regulatory mechanisms, 
mainly glucagon secretion from α-cells of the pancreas (Layden et al., 2010). Glucagon acts to 
increase hepatic glucose production, through induction of glycogen breakdown and/or de novo 
synthesis of glucose. The liver responds to glucose fluctuations, and regulates glucose release 
into the bloodstream.  Additionally, circulating catecholamines, amino acids and hormones 
influence the insulin/glucagon ratio. The feedback loop regulating the glucose homeostasis is 
dependent on the continuous crosstalk between endocrine cells of the pancreas and insulin 
sensitive tissues (Kahn et al., 2014). 
Metabolic disturbances 
In the case of insulin resistance, β-cells sustain normal glucose tolerance by increasing the 
insulin output to compensate for the tissue insensitivity to the hormone (Ferrannini et al., 2005; 
Kahn et al., 2014). If β-cells fail to increase insulin secretion, an increase in plasma 
concentration of glucose follows.  
Type 2 diabetics have exhibited both quantitative and qualitative perturbations of insulin levels 
(Rahier et al., 2008). Deterioration of β-cell function and reduction in β-cell mass inhibit the 
insulin capability of the pancreas (Kahn et al., 2014). A reduction in β-cell number is partly 
explained by glucolipotoxicity and amyloid deposition, triggering apoptosis through oxidative 
and endoplasmic reticulum stress (Jurgens et al., 2011). Amylin is normally co-secreted with 
insulin, when aggregated the formation of islet amyloid occurs. Glucolipotoxicity refers to the 
deleterious effects of increased levels of glucose and fatty acids on β-cells, increasing cellular 
lipids and eventually leading to apoptosis (Poitout et al., 2010). The combination of excessive 
levels of fatty acids and glucose, therefore leads to decreased insulin secretion, impaired insulin 
gene expression, and β-cell death by apoptosis. 
Although insulin resistance and β-cell dysfunction is key in understanding the pathogenesis of 
type 2 diabetes, the combination of environmental and genetic factors also contribute to the 
disease. Genetic variation might predispose some individuals for the development of disorders 
related to the environment; diet and physical activity (McCarthy, 2010). 
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1.2 Methylmercury 
Methylmercury (MeHg) is a highly toxic contaminant, arising from both natural and 
anthropogenic sources (ATSDR, 1999). Considerable emissions of mercury arise from natural 
sources, such as crust degassing, volcanoes, oceanic sediments and forest-fires and is further 
accompanied by man-made contributions like combustion of fossil fuels, chloralkali-
manufacturing and coal mines (Morel et al., 1998). 
Mercury exists in three basic forms: elemental (liquid), organic (mercury and carbon) and 
inorganic mercury (combined with chloride, sulfur, oxygen, also called salts)(ATSDR, 1999). 
Organic mercury compounds exist in a variety of formations; however, the most common 
organic mercury compound is MeHg. Once in the environment, inter-conversion between these 
compounds readily occurs. MeHg is of particular interest due to its ability to bio accumulate 
and bio magnify in the aquatic food chain. 
The global cycle of Mercury 
The chemical properties of mercury are of great importance when trying to understand the 
movement and deposition of the contaminant (Schaefer et al., 2011). Elemental mercury is a 
volatile compound (Hg0), and the mercuric compound is highly reactive. The global cycle of 
mercury largely unfolds through reduction-oxidation reactions in the atmosphere and surface 
waters. Elemental mercury degasses from soil and surface waters, travels in the atmosphere and 
deposits onto land and surface waters (ATSDR, 1999). Further, the compound is absorbed into 
soil or particles in the sediment, and re-volatilization occurs. This process of emission- 
deposition and re-volatilization represents the challenge of trying to track the movement of Hg 
to its sources.  
Methylation of elemental mercury 
Methylation of mercury is a process where elemental mercury receives a methyl group from an 
organic compound (Morel et al., 1998). The first step in the methylation pathway is the 
conversion of elemental mercury (Hg0), oxidizing to reactive species (Hg2). The oxidation 
process occurs in air or aquatic environments (Mason et al., 1995). Whereas the oxidation 
occurs only to a small extent in fresh water systems, there is a substantial degree of oxidation 
in deep waters. Sulfate-reducing bacteria are responsible for the majority of mercury 
methylation in natural waters and sediments (Morel et al., 1998). Once methylated, the MeHg 
compounds may re-enter the atmosphere or bio- accumulate in the aquatic and terrestrial food 
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chain (ATSDR, 1999). The ability of MeHg to bio magnify in the marine food chain, creates a 
source for human consumption.  
Human exposure to methylmercury  
Humans are exposed to MeHg primarily through consumption of seafood (WHO, 2008). MeHg 
has a strong affinity for Thiols (Rooney, 2007), and is mostly bound to albumin, glutathione 
(GSH) or L-cysteine (Allen et al., 2001; Hirayama et al., 1991; Yasutake et al., 1997) . These 
complexes might predict body distribution of mercury, and possibly enhance mercury 
absorption and tissue accumulation (Hirayama, 1985). The MeHg-cysteine complex is 
structurally analogous to methionine, and thereby gains entry into the cells via amino acid 
carriers (Clarkson and Magos, 2006). MeHg from dietary sources are absorbed in the 
gastrointestinal tract and distributed throughout the body (Clarkson, 1972). Once arrived into 
the bloodstream, MeHg enters the red blood cells, extensively bound to hemoglobin (90%) 
(Kershaw et al., 1980). MeHg appears stable when consumed compared to other mercury 
species, and de-methylation towards less damaging inorganic mercury is slow. The major route 
of MeHg excretion occurs through bile and feces. Approximately 1% of the body burden is 
eliminated daily (Clarkson, 1988). MeHg slowly leaves the body, mostly as inorganic mercury 
in feces.  
Upper Limits in Seafood 
The concentrations of MeHg are minor in most fish species, but accumulation in the marine 
food chain contributes to higher levels in predatory fish, increasing with age and size (VKM, 
2006). The upper limit of all mercury species in fish is set at 0.5 mg/kg (wet weight) (EFSA, 
2012). In the case of some predatory fish (tuna, eel, halibut) the upper limit is set at 1.0 mg/kg. 
Despite potentially higher contents of mercury in these species, they represent a smaller 
proportion of the total fish intake. According to a report from the Norwegian Scientific 
Committee for Food Safety, lean fish contains approximately 0.05-0.08 Hg mg/kg, fatty fish 
contains approximately 0.01-0.1 mg/kg Hg and freshwater fish (pike, trout, perch) contains 
approximately 0.3-0.6 mg/kg (VKM, 2006). A report from Hardangerfjorden showed that the 
average mercury content of some deep-water species (Greenland halibut, tusk) was above 0.5 
mg Hg/kg wet weight (Måge et al., 2011). 
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Tolerable weekly intake 
Tolerably weekly intake of MeHg (expressed as mercury) is 1.3 µg/kg bodyweight/week 
(EFSA, 2012). This is equal to 0.09 mg/week for a person of average body weight (70 kg). The 
average seafood consumption among the adult population in Norway is 70 gram/day (VKM, 
2006). Average intake of mercury from fish and seafood was 0.4 µg/kg body weight/week, 
among participants in the Fish and Game study. In 2006 the PTWI values for MeHg was slightly 
higher (1.6 µg/kg) and only 0.6% of the participants in the Fish and Game study exceeded this 
PTWI.  
MeHg toxicity  
Marine pollution by organomercurials first came to the worlds attention after a major accident 
in Japan in 1953. In a historical perspective, there has been several outbreaks of MeHg 
poisoning through fish-consumption (Eto, 1997; Tsubaki, 1967). The unfortunate outbreaks in 
Minamata bay (1953-1956) and Niigata city (1964-1965) was a consequence of industrial 
release. In 1973 a severe outbreak of MeHg poisoning occurred after consumption of MeHg 
treated grain (Bakir et al., 1973). MeHg poisoning display an array of adverse effects 
(neurological disturbances, impairment of speech, hearing, vision, sensory disturbances, 
tremor, mental disorders) (Ceccatelli et al., 2010) and in severe cases death has been the 
outcome. This comprehensive clinical picture was named Minamata disease. 
The main toxicological organ for MeHg is the brain, and its detrimental effects as a 
neurotoxicant are well established (Ceccatelli, Dare et al. 2010). The evolving brain is the most 
susceptible to damage, and extreme fetal abnormalities were seen after the Minamata accident. 
MeHg readily cross the placental barrier and is excreted in breast milk subsequently reaching 
the fetus at its most fragile states. 
Mechanism of methylmercury toxicity 
A range of mechanisms have been proposed to underpin MeHg toxicity. Essential is the high 
affinity of MeHg for sulfhydryl and thiol groups (Clarkson, 1972). The formation of these 
complexes enables mercury to produce cell injury and apoptosis (Ceccatelli et al., 2010). 
Toxicity may be induced by oxidative stress via increased production of reactive oxygen species 
(ROS), or by a decrease in oxidative defense systems (Sarafian and Verity, 1991). Mercury has 
also been shown to induce mitochondrial dysfunction, which can cause disruption of Ca2+ 
homeostasis through an increase of intracellular Ca2+ or uncontrolled release of Ca2+ from the 
mitochondria due to oxidative stress (Atchison and Hare, 1994; Graff et al., 1997). Additionally, 
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it has been suggested that MeHg is capable of suppressing enzyme activity, interrupt 
microtubule formation, interfere in DNA and protein synthesis and trigger autoimmune 
responses (Ceccatelli et al., 2010).  
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1.3 Introduction to the experiment 
There is great knowledge about the effects of methylmercury on neurological development and 
disorders (Ceccatelli et al., 2010), however, far less is known about the effects on type 2 
diabetes. To our knowledge, the effects of MeHg on obesity development have not been studied. 
In the present investigation, obesity prone C57BL/6 mice were given a chronic dietary exposure 
to mehtylmercury-cysteine complex, implemented in obesogenic diets, during a 13 week 
feeding trial. The contamination pressures in the diets were: 
 Non-supplemented low fat diet (LF) 
 Non-supplemented high fat/high sucrose diet (HF/HS) 
 HF/HS 0.3 mg/kg MeHg 
 HF/HS 1 mg/kg MeHg 
 HF/HS 3 mg/kg MeHg  
 HF/HS 10 mg/kg MeHg 
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1.4 Aims 
The current project aimed to explore the dose-response effects of methylmercury (MeHg) on 
diet induced obesity in mice, evaluating: 
 The effects of MeHg on glucose tolerance and insulin sensitivity, including evaluation 
of glucose stimulated insulin secretion. 
 The distribution and accumulation of MeHg in different organs. 
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2 Materials and Methods 
2.1 Ethical aspect 
This animal experiment is approved by the Norwegian animal research authority and the 
following procedures were performed in compliance with the current guidelines for the care 
and use of laboratory animals (National Research Counsil, 2011). 
2.2 Experimental design 
55 male C57BL/6JBomTac mice purchased from Taconic (Denmark), arrived at the animal 
facility at NIFES (Norwegian institute of nutrition and seafood research) at 7-8 weeks of age. 
Obesity prone C57BL/6J mice is appropriate due to its ability to develop obesity and type 2 
diabetes (Surwit et al., 1995) Initially the animals were acclimatized, during this 5-day period, 
they were fed a chow diet and were given ad libitum access to water.  
After acclimatization, the mice were weighed using a Mettler Toledo weight and scanned using 
a magnetic resonance instrument (Bruker Minispec LF50mq7.5) which provides a measurement 
of lean tissue, fat and fluid.  The weights of the animals were ranging between 24.52±2.15 g, 
and they were divided into 6 groups (n=8) based on these recordings to achieve an equal 
baseline mean weight in each group.  
A specific amount of food was weighed, registered, and fed to the animals three times a week 
(Monday, Wednesday, Friday) for 13 weeks. The remains were collected before feeding, and 
subsequently weighed and registered. Access to water was unlimited at all times. The animals 
were weighed once a week throughout the experiment. On the basis of these weekly recordings, 
development of the animals was tracked. 
Housing 
The mice were housed in individual plastic cages in a controlled environment (temperature 
22±2 C° and humidity 50±5 %) with a 12-hour light/dark cycle. The cages were enriched with 
wooden chip bedding, a plastic house and nesting material.  The animals were given clean cages 
and new bedding once every second week.  
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Preparation of diets 
Experimental diets were prepared at NIFES based on a standard low fat (LF) and high fat/high 
sucrose (HF/HS) setup. Appendix I: Table A.1 and A.2 display dietary ingredients of the 
different diets as well as the suppliers. The different components were weighed in using a 
laboratory weight (Mettler Toledo PG42002-S/PH), and mixed in a blender (Crypto Peerless 
EF20 blender).  
A stock solution of MeHgCl was made by dissolving 1 g MeHgCl (Sigma Aldrich) in 50 ml 
ethanol. L-cysteine was prepared by dissolving 7.5 g of L-cysteine in 1 litre of distilled water. 
This solution was prepared fresh prior to every batch of feed. An equimolar mixture was made 
by combining these solutions, and the mixture was added to the diets. For the control diets an 
1:1 solution of ethanol and water was added. Aliquots of the methylmercury-cysteine (MeHg-
Cys) solution was added to the feed mixture in combination with 30 percent water, according 
to Appendix I: Table A.3. The supplementation of MeHg-cysteine was performed by trained 
personnel. Color was added to ensure separation of the different doses, throughout the 
experiment. Finally, the feed mixture was sculptured in a pellet-mold, frozen and subsequently 
dehydrated using a vacuum freeze-dryer (Christ, Lyo chamber guard). The lipophilization 
process occurs through, a direct conversion from ice to vapor. Feed was contained at -20 C° to 
maintain quality of the diets. 
Each group received different diets; HF/HS diet supplemented with increasing concentrations 
of MeHg (0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg). A non-supplemented low fat diet and high 
fat/high sucrose diet were used as references (Betty L. Black, 1998; Petro et al., 2004). The 
macronutrient composition of the background diets are shown in fig. 2.1. To verify dietary 
contents, a random selection of feed was analyzed. The mercury content was on average 0.54, 
0.83, 2.4, 8.29 mg/kg. The total contents of the diets are provided in Appendix I: Table A.1. 
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Figure 2-1. Distribution of fat, sugar, starch and protein in the experimental diets. A: Low fat control diet. B: 
Non-supplemented HF/HS was the control diet and the background diet for MeHg supplementation. 
Food-Intake and Weight Development 
The mice participated in a 13-week feeding-trial. They were fed three times a week (Monday, 
Wednesday, and Friday) for 13 weeks. At feeding, the amount of pellets and residues were 
registered by weighing.  Based on total body weight gain and food intake, feed efficiency (the 
amount of calories necessary to produce 1 gram of weight gain) was calculated, using the 
formula below; 
𝐹𝑒𝑒𝑑 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 = (Body weight gain (g))/(Food intake (Kcal)) 
Body scan 
Mice were subjected to a non-invasive examination; magnetic resonance scan to reveal body 
composition (body weight, fat mass, lean mass and water content). Scanning was performed at 
baseline and after 6 and 9 weeks of feeding.  
Collection of feces 
Feces was collected after 3 and 9 weeks of feeding. The mice were transferred to clean cages 
with paper bedding for a 7 days period, food intake and weights were recorded, and feces was 
collected at the end of the period. Samples were weighed, stored in small containers at -20°C 
awaiting further analysis. Subsequently, the total fat content of feces was measured and 
apparent fat digestibility (AFD) was calculated using the formula below: 
𝐴𝐹𝐷 = ([Fat consumption] − [Fecal excretion])/([Fat consumption]) ×  100 
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Insulin Tolerance test 
At the end of the exposure period (11 weeks) an insulin tolerance test (ITT) was performed.  
The animals were moved to small cages. Baseline blood glucose was measured in fed state and 
an intraperitoneal injection of insulin was administered at a dose of 1U/kg lean bodyweight. 
Blood glucose levels were measured at 15, 30, 45 and 60 minutes. Further, the homeostasis 
model assessment was used to evaluate insulin resistance (HOMA-IR). Fasting insulin and 
glucose levels were used in order to calculate HOMA-IR by the following formula: 
HOMA − IR = [Fasting glucose (mmol/L)]   ×  [Fasting insulin (mU/L)]  /22.5 
 
Oral Glucose Tolerance test 
An Oral Glucose tolerance test (OGTT) was performed after 10 weeks of feeding 
(Andrikopoulos et al., 2008).  The individual glucose load was determined based on the lean 
mass of each animal. Initially, the mice were weighed and placed into small cages, with ad-
libitum access to water. After 6 hours of fasting they were weighed again, baseline was 
established and they were given an oral dose of 3 mg/g lean bodyweight glucose solution (200 
mg/ml glucose injection fluid) using an oral gavage syringe. Blood glucose was measured at 
15, 30, 60 and 120 minutes using a glucometer (Contour next blood glucose meter). Blood 
samples were collected in EDTA containing tubes, centrifuged at 2500g at 4°C for 10 minutes. 
Plasma was transferred to new tubes and stored at -80 C°. Subsequently, insulin levels in plasma 
were quantified using enzyme-linked immunosorbent assay (ELISA) kit for mouse (DRG 
Instruments, GmbH, Germany). Analysis was performed according to manufacturers manual 
(DRG Instruments, GmbH, Germany) and the ELISA kit reagents are listed in Appendix II: 
Table A4. 
2.3  Sampling 
After 13 weeks of feeding the experiment was terminated. Before euthanization, the mice were 
randomly fed, given ad libitum access to water and weighed. The termination process was 
performed by trained personnel. The animals were anaesthetized with Isoflurane (Isoba-vet, 
Schering Plough, Denmark) using an anesthesia unit (Univentor 400 Anesthesia Unit 
(Univentor Limited, Sweden) and blood collected by cardiac puncture. The sternum was opened 
using a scalp and a syringe was placed gently into the heart to collect blood samples. The 
samples were immediately collected in EDTA anticoagulant tubes, centrifuged at 2500g in 4 
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C° for 5 minutes, separating red blood cells and plasma. One mice from the non-supplemented 
HF/HS control group, unexpectedly deceased during the experiment.  
Tissue collection and storage 
Liver, kidneys, spleen, brain, heart, tibialis muscle and pancreas were collected. Additionally 
four fat depots were excised; visceral white adipose tissue depots; epididymal (eWAT) and 
retroperitoneal (rWAT), the subcutaneous white adipose tissue depot; inguinal (iWAT) and the 
brown adipose tissue depot; intrascapular (iBAT). Organs were dissected out, weighed and 
flash-frozen in liquid nitrogen. Samples were kept on dry ice during the sampling process and 
stored at -80 C° for further analysis. 
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2.4 Quantitative Real Time Polymerase Chain Reaction 
Quantitative real time polymerase chain reaction (qPCR) was performed to quantify the relative 
gene expression level in mouse liver. The expression was normalized to a housekeeping-gene 
(TATA binding protein) known to transcribe at a relatively constant level. 
Tissue homogenization and RNA extraction 
Principle: The tissues were homogenized in Trizol. Trizol contains phenol and guanidine salts 
that takes part in solving biological material and denaturing protein. Chloroform separates RNA 
from the proteins and deoxyribonucleic acid (DNA). RNA is precipitated from the water phase 
by adding Isopropanol. The RNA is solved in ddH2O. 
Procedure: Before starting the procedure all surfaces and equipment were cleaned with RNase 
Zap and tissue samples transferred to 1.5 ml RNAse free tubes after thawing on ice. 3 Zirconium 
beeds and 1 ml Trizol was added into the tubes, followed by homogenization at 6000 rpm, 3x15 
sec. The tissue samples were centrifuged for 10 minutes at 12 000g 4 °C, and the homogenate 
transferred to a second tube and incubated for 5 minutes at room temperature. The homogenate 
was centrifuged for 10 min at 12 00g. 200µl chloroform was added, and the tubes were manually 
shaken for 15 sec. The samples were incubated at room temperature for 2 minutes and 
centrifuged for 15 min at 12 000g 4 °C. The aqueous phase was transferred to a clean tube, 500 
µl Isopropanol was added and the tubes were gently mixed. The samples were incubated for 10 
min at room temperature and 10 min at 4 °C, followed by 30 min of centrifuge at 12 000*g. 
The supernatant was removed with vacuum suction, 1 ml cold 75%ETOH was added and the 
tubes were whirled and centrifuged for 5 minutes at 10 000*g. This step was repeated one time. 
Then absolute EtoH was added, whirled and centrifuged at 13000*g for 5 minutes. The 
supernatant was removed to allow the RNA pellet to dry. The pellets were dissolved in 50-200 
µl of ddH2O, depending on the size of the pellets. RNA concentrations were measured with a 
Nano Drop. A260/A280 ratio between ≥1.8-2.1 is preferable. <1.80 might indicate Phenol, DNA 
or protein remnants in the sample. Chemicals and reagents used during this procedure are listed 
in Appendix III: Table A5.  
RNA Precipitation 
Principle: Precipitation is a process used to improve the quality of the sample by altering the 
A260/A230 ratio, which is an indicator of the purity of the sample. Remaining residues of salt (or 
other inhibiting factors) might lower the ratio that preferably locates at >1.8. 
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Procedure: The samples were thawed on ice. 0.1 volume 3 Molar NaAc pH 5.2 and 2.5 volume 
of absolute EtOH was added. The samples were incubated for 1 hour at -80°C. After incubation 
the samples were centrifuged at 12 000g for 15 minutes at 4°C. The supernatant was carefully 
removed with vacuum suction, 1 ml 75% EtOH was added and the samples whirled. 
Centrifuged at 12000g for 5 minutes at 4°C, remaining liquid was removed again, and 30-200µl 
DEPC H20 was added, depending on the size of the pellets. Chemicals and reagents are listed 
in Appendix III: Table A6. 
RNA Quality  
Principle: RNA 6000 Nano is a miniature edition of the RNA electrophoresis method. The 
RNA is separated by size in the channel system of the chip. The migration of RNA is detected, 
by which RNA integrity number (RIN) can be calculated.  
Procedure: 12 representative samples were thawed on ice. The RNA6000 Nano kit was 
brought to room temperature. The light sensitive RNA Nano Dye was kept in a dark container. 
550 µl of gel matrix was filtered and centrifuged at 1500g for 10 minutes, and a 32µl aliquot 
was prepared. The Gel Dye mix was whirled and spinned down. 0.5 µl RNA Nano dye was 
added to the filtered gel matrix. The samples were whirled and centrifuged at 13 000g for 10 
minutes. The RNA concentration was adjusted to 100-500µg/µl. The bio analyzer was prepared 
by decontaminating the electrodes using a wash-chip filled with water and RNaseZap. Before 
loading the samples, the Nano chip was placed in a priming station. The microchip contains 16 
wells were sample and reagents are loaded in a specific order. 9µl gel dye-mixture was added 
into three of the wells, the priming station closed, incubated and then opened before the 
complete loading was performed. Further, 5 µl of marker was added to all the wells (except 
those containing gel). 1µl ladder was added into one single well. The RNA samples incubated 
for 2 minutes at 70°C and 1µl RNA sample was added into 12 wells. The chip was whirled for 
1 minute at 2400rpm (IKA vortex mixer), and analyzed on the Bio analyzer within 5 minutes. 
See Appendix III: Table. A7 for a detailed list of chemicals and reagents and figure. A.1 for the 
RIN numbers obtained from the bio analyzer. 
Reverse transcriptase reaction 
Principle: RNA is transcribed to complementary DNA (cDNA) by the enzyme reverse 
transcriptase. cDNA is a more stable compound and can be interpreted by the qPCR. 
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Procedure: The samples were thawed on ice, and kept on ice for the entire procedure. The 
concentration of RNA in the samples were adjusted on the nano drop until they had a 
concentration of 50ng/µl ±5%. 3 µl of RNA from all the samples was added into single tubes. 
An aliquot of 90µl was made, and adjusted to 100ng/µl±5% on the nano drop. Based on the 
RNA mixture the standard curve was set up with concentrations from 100- 50- 25- 12,5- 6,25- 
3,125 ng/µl. 
Reverse transcriptase reagents were thawed on ice, and enzymes kept on a freezing block in a 
clean room. A 96 well RT plate was prepared as described in Appendix III: Table A8. 40 µl 
reverse transcriptase mix was added into all the wells. 10 µl RNA/well was added to the RT 
plate (Standard curve triplicates and sample duplicates). As well as two negative controls; Non-
amplification control (nac), containing no enzyme and Non-template control (ntc) containing 
no RNA. The cDNA plate was centrifuged for 1 minute at 50g and placed in the PCR machine. 
The PCR machine was set on a specific temperature program (10 minutes for 25C°, 60 minutes 
for 48C°, 5 minutes for 95C°) and the cDNA plate was stored at -20 C° until Real time qPCR 
analysis. 
Real Time PCR 
Principle: The Real time PCR method is based on the amplification of small DNA sequences 
coding for the gene of interest. The amplification of DNA is an exponential process detectable 
by fluorescence.  
Procedure: The cDNA plate was thawed on ice and diluted by adding 50 µl ddH20. 
Centrifuged at 1000g for 1 minute and whirled at 1300 rpm for 3 minutes. Reagents were 
thawed on ice at the RNA-free lab. The real time reaction mix was made by mixing the reagents 
in Appendix III: Table. A8. 
Using a robot (Biome 3000 Laboratory Automation 31 Workstation, Beckman Coulter, USA).  
8µl of reaction mix and 2µl cDNA was added to a 384 well real-time PCR plate.  An optical 
adhesive cover was placed on top of the plate and it was centrifuged at 1500g for 2 minutes 
Finally, the cDNA plate was placed in a Light cycler 480 and analyzed by a real-time PCR 
program according to manufacturers manual. Primers are shown in Appendix III: Table A9. 
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2.5 DMA80 – Direct Mercury Analyzer 
Principle: The sample is dried through several steps of combustion, chemically decomposing  
the analyte from the sample trough thermolysis. A constant oxygen flow carries the thermolytic 
products through a catalyst bed, trapping interferences. Remaining mercury species are reduced 
to elemental Hg and trapped in a gold amalgamator. The amalgamator is reheated, releasing 
mercury vapor into a single beam of light at a specific wavelength. The amount of mercury in 
the sample is proportional to the absorbance at 254 nm, read by atomic absorbance 
spectrophotometry.  
Procedure: Total Hg concentrations were measured in organs and feces from each individual 
mouse using atomic absorption spectrophotometry (Direct mercury analyzer, DMA80). The 
samples were weighed into a nickel boat and positioned in the auto sampler. Sample 
preparations were not required, and results were obtained directly from a software.  
Certified Reference Material (CRM) for trace metals were included in duplicates, twice at every 
run to assess the accuracy/quality of the analysis. Oyster tissue (37.1 ng/g ±7.40) and TORT-3 
Shellfish tissue (292±58μg/kg) were used, due to correspondent concentration levels compared 
to the respective samples. The mean values obtained from certified reference material were 
ranging within 2 standard deviations. Despite one DMA80 run, were one of the certified 
reference materials were within 3 standard deviations. Blanks were regularly distributed 
throughout every run, to clean the instrument and to exlude memory effect from one sample to 
another.  
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2.6 Histology 
In order to investigate the morphology of the insulin secreting organ, pancreatic tissue was zinc-
formalin fixed, paraffin embedded pancreas specimens were cut into 5 um sections and stained. 
A random selection of tissue from each group was stained with hematoxilin/eosin, and Hoechst 
33258. The islet mass and cell nuclei were assessed, respectively. Reagents and solutions are 
listed in Appendix IV: Table. A10. 
Fixation with zinc formalin fixative 
The fixation medium preserves the structure and morphology of the tissue, by inhibiting 
enzymatic autolysis and degradation due to bacteria. A small section of pancreatic tissue was 
placed in a (histology) cassette and immediately fixated in zinc formalin fixative, diluted in 0.1 
M Phosphate buffer (PB). The next morning the cassettes were washed once in PB and 
contained in PB until dehydration. 
Dehydration and paraffin embedding 
After preservation, the tissues were dehydrated in a progressive series of ethanol dilutions, 
gradually removing fixation medium and water. The time schedule is shown in Appendix IV: 
Table. A11. When dehydrated, tissue was transferred to xylene, and further infiltrated in liquid 
paraffin. Finally, tissues were embedded in paraffin to form blocks, using a paraffin embedding 
center (Microtom international, Germany). 
Sectioning with microtome and staining 
The paraffin blocks with tissue were positioned on the microtome (Leica RM 2165) and cut in 
sections of 5 µm. Sections were transferred to heated water (33-35°C) (Slide warmer SW 85). 
A small amount of Methanol was added to the water to help stretch the tissue. Tissues were 
collected with a microscope slide and left to dry over the weekend. Further, the tissue was 
stained in order to visualize the cell structures in a microscope. Prior to staining the slides were 
heated at 57°C for 60 minutes in a heating cabinet. Twenty random sections of pancreas from 
HF/HS control and all treatment groups were rehydrated, stained and dehydrated following the 
procedure in Appendix IV: Table A12. Hematoxilin and eosin was applied to stain the nucleus 
and the cytoplasm of the cell, respectively. After staining the slides were mounted with xylene 
based glue, a cover glass and left to dry. Additionally, twenty random sections of pancreas from 
HF/HS control and 10 mg/kg was rehydrated and stained following the procedure in Appendix 
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IV: Table A13. Sections were stained with a fluorescent dye (Hoechst 33258) to identify nuclei. 
Tissue slides were mounted with fluorescent mounting medium, a cover glass and left to dry. 
Microscopy and image analysis 
The pancreas sections from the control group (HF/HS) and the 10 mg/kg MeHg-group were 
compared using a binocular microscope (Olympus BX 51 binocular microscope). Twenty 
sections stained with hematoxilin/eosin were assessed in the microscope. Four representative 
sections of HF/HS and 3 sections of 10 mg/kg group was used to measure the volume of 
Langerhans islets of the pancreatic section.  Image J, measurement tool was used to outline the 
islets, and total area in order to calculate the islet mass of the sections. Finally, twenty sections 
stained with Hoechst 33258 were assessed in the microscope to identify nuclei.  
2.7 Statistical analysis 
Statistical methods were used in the search for statistically significant differences between the 
different groups in the experiment. All data was continuously entered into excel to be able to 
follow development in the experiment. Statistics were performed using Graphpad Prism 5.0. 
D’Agostino Pearson omnibus test was used to assess normality of distributions of each 
treatment. Outliers were detected using Grubb’s test for outliers, and significant outliers were 
removed. Data was analyzed by One way analysis of variance (ANOVA) followed by Dunnet’s 
multiple comparison test (Unless otherwise stated). All treatment groups were compared to high 
fat/high sucrose control. Low fat-control was included as a reference. Differences between 
groups were considered significant when p<0.05. Data were presented as mean ±SEM. 
STATISTICA: Repeated measurements ANOVA was performed on data from the curves of body 
weight development, ITT, OGTT and GSIS. All data were tested for normality of distributions 
(PP plot) and homogeneity of variance (Levenes test).  
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3 Results 
3.1 Body weight development and feed intake 
To investigate the effect of methylmercury (MeHg) on the development of obesity and diabetes, 
a 13 week feeding experiment was performed. Obesity-prone C57BL/6 mice were fed a high 
fat/high sucrose diet, spiked with increasing amounts of methyl mercury. A non-supplemented 
low fat diet and a high fat/high sucrose diet was included as reference. The development in 
body weight and feed intake are presented in fig. 3-1. 
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Figure 3-1. Body weight gain and feed intake in the different experimental groups (n=8). A: Weekly body weight 
(g) recording in all treatment groups during 13 weeks of feeding. Repeated measurements ANOVA not significant. 
B: Total weight gain (g). C: Total energy intake (Kcal) during feeding trial. D: Feed efficiency. All values 
expressed as mean ± SEM. * Refer to significant differences from non-supplemented high fat/high sucrose group 
according to posthoc, Dunnet’s test (*P<0.05, **P<0.005, ***P<0.0005*).  
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MeHg did not significantly increase body weight development or weight gain (Fig. 3-1 A). As 
expected, mice fed the low fat reference diet, gained less weight than all HF/HS groups. In fact, 
the non-supplemented HF/HS group gained the most weight, considering all groups. 
Consequently making the MeHg exposed groups, randomly distributed between the LF and the 
HF/HS diets. Conversely, the total weight gain was significantly lower in 1 mg/kg and 10 mg/kg 
MeHg fed mice compared to HF/HS group (Fig. 3-1 B).  
To exclude the possibility that the modest weight gain in 1 mg/kg and 10 mg/kg groups were 
explained by a reduction in total energy intake, total caloric intake was measured and feed 
efficiency and was calculated (Fig. 3-1 C and D). All groups displayed a similar total energy 
intake, despite contamination pressure (Fig. 3-1 B). Thus implying an increase in MeHg had no 
effect on the energy intake. The amount of calories necessary to produce 1 gram of weight gain 
was calculated, to evaluate if MeHg concentrations had an impact on energy efficiency. The 
feed efficiency was significantly lower in the 10 mg/kg MeHg fed mice compared with the non-
supplemented HF/HS group (Fig. 3-1 D) and thereby had twice the energy cost to establish the 
same weight gain as opposed to the HF/HS group.
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3.2 Whole body analysis 
To gain further insight on whether the restricted weight gain in mice at different exposure 
regimens was due to changes in fat mass or lean mass, an MRI-scan was performed. Data from 
the scan are shown in fig. 3-2. 
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Figure 3-2. Body composition, distinguished between fat and lean mass (g) at baseline, 6 and 9 weeks of feeding. 
A: Lean mass (g) B: Fat mass (g) One-way Anova was performed to assess differences within each group. Baseline 
of HF/HS was compared to baseline of all treatment groups, and likewise for 6 and 9 weeks. All values expressed 
as mean ± SEM. * Refer to significant differences from non-supplemented high fat/high sucrose group according 
to posthoc. Dunnet’s test (*P<0.05, **P<0.005). 
MeHg exposure did not significantly alter the lean mass of the animals, according to the MRI-
scan (Fig. 3-2 A). Comparison within each individual group displayed no significant differences 
in the lean mass of the animals (Fig. 3-2 A). Moreover, no differences emerged when comparing 
any of the groups exposed to MeHg, compared to HF/HS control. Indicating that changes in 
body weight probably occurred due to a variation of fat mass. 
Comparison within each individual group showed no significant differences in the fat mass of 
the animals. Concurrent with the limited weight gain in mice exposed to 10 mg/kg, they 
exhibited a significant reduction in fat mass after 9 weeks of feeding (Fig. 3-2 B).  
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3.3 Fat depot masses 
To explore the effects of the experimental diets on the adipose tissues of the mice, four different 
fat depots were dissected out and weighed. The weight of white adipose tissue depots; visceral, 
subcutaneous and abdominal, as well as the intrascapular brown adipose tissue, are shown in 
fig. 3-3, respectively.  
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Figure 3-3. The weight of four different adipose tissue depots (g). A: Epididymal adipose tissue B: Inguinal white 
adipose tissue C: Retroperitoneal adipose tissue D: Intrascapular brown adipose tissue. All values expressed as 
mean ± SEM. * Refer to significant differences from non-supplemented high fat/high sucrose group according to 
posthoc. Dunnet’s test (*P<0.05). P for trend (P=0.05-0.1). 
Mice fed the 10 mg/kg MeHg diet, exhibited a significant decrease in visceral fat, compared to 
the HF/HS control diet (Fig. 3-3 A). Equally, the subcutaneous fat pad was significantly 
decreased in 10 mg/kg, compared to that of HF/HS control (Fig. 3-3 B). Further, the 10 mg/kg 
MeHg group displayed a trend towards reduced abdominal fat depots (Fig 3-3 C), whereas no 
significant alterations of fat mass was evident in brown adipose tissue (Fig 3-3 C-D). Besides 
mice fed the highest exposure regimen, no significant changes were seen in fat depot masses. 
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3.4 Apparent fat digestibility 
Further, feed digestibility was calculated, to investigate whether the observed differences in 
energy efficiency originated from differences in energy absorption. Feed intake and fecal 
excretion of mice were recorded for one week. Subsequently, the total fat content was measured 
in feces and apparent fat digestibility (AFD) was calculated. Apparent digestibility is presented 
in fig. 3-4. 
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Figure 3-4. Apparant fat digestibilty. A: AFD (%) after 3 weeks and 9 weeks of MeHg exposure. All values 
expressed as mean ± SEM.  
MeHg exposure did not significantly alter the fat digestion in any of the groups (Fig. 3-4 A). 
Fat digestion from the third week of the experiment, was comparable to the digestion after nine 
weeks, an indication that excretion remained stable throughout the experiment. 
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3.5 Effects of methylmercury on glucose tolerance in mice 
In order to explore the effect of MeHg on glucose tolerance, an oral glucose tolerance test was 
performed. Mice were fasted for six hours and given an oral dose of glucose based on their 
body weights. Blood glucose was measured, followed by glucose measurements as 15, 30, 60 
and 120 minutes. Blood glucose responses during the test are shown in fig. 3-5. 
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Figure 3-5. OGTT performed after 10 weeks of methyl mercury exposure. A: Levels of blood glucose at baseline, 
15 min, 30 min, 60 min, 120 min after glucose administration, in all groups. Repeated measurements ANOVA not 
significant. B: Area under the curve. C: Baseline levels of blood glucose. D: Glucose levels 15 minutes after 
glucose administration. E: Delta blood glucose; (15-0 min). All values expressed as mean ± SEM. * Refer to 
significant differences from non-supplemented high fat/high sucrose group according to posthoc Dunnet’s test 
(*P<0.05). P refer to a trend (P=0.05-0.1). 
Results from the oral glucose tolerance test showed that MeHg was associated with a reduction 
in glucose tolerance in the 0.3 mg/kg MeHg group, indicated by significantly elevated glucose 
area under the curve, compared to the control group (Fig 3-5 B). When assessing the OGTT 
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curve, mice fed 0.3 mg/kg MeHg had a sustained peak in blood glucose and a reduced glucose 
disposal from the blood, although not significant. All groups exhibited a normal response, with 
a peak in blood glucose 15 minutes after glucose administration followed by normalization of 
glucose levels after two hours, but no significant differences were observed (Fig 3-5 A).  
Fasted plasma levels of glucose were similar between the experimental groups (Fig. 3-5 C). 15 
minutes after glucose administration, all groups displayed a similar response with elevated 
levels of glucose, as expected (Fig. 3-5 D). Further, when assessing the pancreatic response to 
a glucose load (15-0 min), no significant alterations were observed between exposure regimens 
(Fig. 3-5 E). Yet, a trend towards higher glucose levels were seen in mice exposed to 3 mg/kg 
MeHg (P=0.0766). Repeated measurements ANOVA detected no significant differences 
between diets on the glucose tolerance of the mice (Fig 3-5 A). 
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3.6 Effects of methylmercury on glucose stimulated insulin secretion in mice 
To explore the potential effects of MeHg on glucose stimulated insulin secretion (GSIS), blood 
samples were collected during the OGTT at baseline and after 15 and 30 minutes. Plasma from 
these samples were analyzed using a mouse ELISA kit as previously described. The Insulin 
levels during the OGTT are presented in fig. 3-6. 
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Figure 3-6. Glucose stimulated insulin secretion (GSIS). Repeated measurements ANOVA not significant A: 
Levels of insulin in all experimental groups at baseline, 15 and 30 minutes after glucose administration. B: Area 
under the curve C: Basal insulin concentrations D. Plasma insulin concentration 15 minutes after glucose 
administration. E: Delta insulin (15-0 minutes). All values expressed as mean ± SEM. * Refer to significant 
differences from non-supplemented high fat/high sucrose group according to posthoc. Dunnet’s test (*P<0.05, 
**P<0.005). P refer to a trend (P=0.05-0.1). 
Methyl mercury significantly decreased basal insulin levels of mice fed 10 mg/kg MeHg, 
compared to HF/HS control (Fig. 3-6 C). Although not significant, 10 mg/kg had the lowest 
glucose stimulated insulin secretion at all times, while 1 mg/kg MeHg and 3 mg/kg MeHg had 
the most elevated glucose stimulated insulin levels.  
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AUC of the GSIS curves tended to be higher in 1 mg/kg and 3 mg/kg, but not significantly 
elevated (3-6 B). 15 minutes after glucose administration, insulin levels were highest in mice 
exposed to 1 mg/kg and 3 mg/kg and lowest in the 10 mg/kg MeHg group, but no significant 
differences were observed (Fig. 3-6 D). Also when assessing delta insulin, 1 mg/kg and 3 Mg/kg 
MeHg mice displayed a tendency towards elevated insulin levels compared to HF/HS. When 
comparing all MeHg diets by repeated measurements ANOVA, we observed no significant 
differences on glucose stimulated isnulin secretion (3-6 A). 
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3.7 Effects of Methylmercury on insulin tolerance in mice 
To explore the potential effect of MeHg on the development of insulin resistance, an insulin 
tolerance test (ITT) was performed. An intraperitonal insulin injection was given to the mice in 
fed state and the ability of insulin to remove glucose from the blood was measured. To assess 
insulin resistance, HOMA-IR was calculated. The effects of methyl mercury on insulin 
tolerance are shown in fig. 3-7. 
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Figure 3-7.  ITT performed after 10 weeks of methyl mercury exposure. A: HOMA-IR. B: The alteration of blood 
glucose after insulin administration. Repeated measurements ANOVA not significant.  C: Area under the curve. 
All values expressed as mean ± SEM. * Refer to significant differences from non-supplemented high fat/high 
sucrose group according to posthoc. Dunnet’s test (*P<0.05, **P<0.005). 
MeHg did not significantly impair insulin resistance in mice at any of the exposure regimens 
according to repeated measurements ANOVA (Fig. 3-7 B). On that note, baseline glucose levels 
were approximately 8-10 mMol/L across the groups followed by a rather synchronous decline 
towards thirty minutes, and a slight elevation after thirty minutes. (Fig. 3-7 B). One hour after 
the glucose administration, HF/HS control had the highest blood glucose levels and 10 mg/kg 
fed mice had the lowest, although not significant. Thereby, displaying the same pattern as seen 
in body weight development. AUC under the ITT curves were not significantly different in the 
MeHg exposed groups, compared to HF/HS control (Fig 3-7 B). 
When assessing HOMA-IR, mice fed the highest exposure regimen (10 mg/kg MeHg) 
displayed significantly higher insulin sensitivity, compared to HF/HS (Fig. 3-7 A). Again, 
suggesting that insulin sensitivity might be inversely associated with body weight. 
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3.8 Relative gene expression in mouse liver 
The liver plays a major role in metabolic regulation and detoxification of pollutants, thus 
representing a central organ in the metabolism of nutrients like lipids and glucose in addition 
to degradation of toxic chemicals. HF/HS diets are known to cause obesity and metabolic 
disorders, such as the onset of hepatosteatosis and changes in expression of genes involved in 
lipid, glucose metabolism and inflammation. The livers from randomly fed mice were used to 
purify RNA and measure relative gene expression, to explore the impact of MeHg exposure on 
gene expression (Fig. 3-8). 
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Figure 3-8. Effect of MeHg on expression of genes involved in metabolic regulation, relative to that of TATA 
binding protein (TBP) (housekeeping gene). A: Acc1. B: Fas. C:Ppar γ. D: G6pc. E: Pck1 F: Foxo1. All values 
expressed as mean ± SEM. * Refer to significant differences from non-supplemented high fat/high sucrose group 
according to posthoc. Dunnet’s test (*P<0.05). 
 
Unexpectedly, high fat/high sucrose feeding, did not significantly alter the gene expression of 
key genes involved in hepatosteatosis nor lipogenesis, regardless of contamination pressure 
(Fig. 3-8 A-C). Similarly, expression of genes involved in fatty acid oxidation and 
gluconeogenesis did not differ significantly in response to progressive MeHg exposures (Fig. 
3-8 D-F). Additional genes were assessed, yet no significant differences were detected 
(Appendix V: Figure A2 and A3). 
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3.9 The fecal excretion of mercury 
To explore the elimination of MeHg at different exposures, feces was collected and 
subsequently analyzed using direct mercury analysis (DMA80). Fecal Hg concentrations after 
three and nine weeks are presented in Figure 3-9. 
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Figure 3-9. After 3 and 9 weeks of feeding on MeHg-containing diets, total mercury content was quantified in 
feces (mg/kg Hg). A: Fecal Hg after 3 weeks. B: Fecal Hg after 9 weeks.  All values expressed as mean ± SEM. * 
Refer to significant differences from non-supplemented high fat/high sucrose group according to posthoc. 
Dunnet’s test (*P<0.05, **P<0.005, ***P<0.0005, ****P<0.0005). 
The fecal secretion of mercury (Hg) increased concomitantly with MeHg concentrations in the 
diets (Fig 3-9). After 3 weeks of exposure, the amount of MeHg in feces was significantly 
higher in the 3mg/kg and 10 mg/kg group compared to the non-supplemented HF/HS control 
(Fig. 3-9 A). 6 weeks later, MeHg secretion occurred in the same pattern, and was still 
significantly elevated with progressive MeHg exposures (Fig 3-9 B). Indicating that the 
elimination of mercury was relatively stable throughout the experiment. 
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3.10 Organ masses and tissue accumulation in methylmercury exposed mice 
To examine if dietary exposures influenced on the organ mass of the mice, organs were 
dissected out and weighed. To gain further insight on the distribution of mercury in the body, 
the cumulative effects of MeHg were assessed in several organs. Hg accumulation was 
investigated by direct mercury analysis (DMA80) The mass (g) and Hg accumulation of liver, 
pancreas, muscle and eWAT are presented in fig. 3-10. 
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Figure 3-10. Effects of progressive MeHg exposures on organ masses and tissue accumulation. A: Liver mass (g) 
B: Muscle mass (g) C: eWAT mass (g). D: Pancreas mass (g) E: [Hg] Liver (mg/kg) F: [Hg] Muscle (mg/kg). G: 
[Hg] eWAT (mg/kg) H: [Hg] Pancreas (mg/kg). All values expressed as mean ± SEM. * Refer to significant 
differences from non-supplemented high fat/high sucrose group according to posthoc. Dunnet’s test (*P<0.05, 
**P<0.005, ***P<0.0005) ****P<0.0005). 
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MeHg proclaimed no effects on liver-, pancreas- and muscle mass in mice, regardless of 
contamination pressure (Fig. 3-10 A, B and D). However, 10 mg/kg MeHg fed mice exhibited 
a significant decrease in eWAT (Fig. 3-10 C). Furthermore, MeHg did not alter organ masses 
of kidney, spleen and heart, at any exposure (Appendix V: Figure A4). 
Tissue accumulation of mercury (Hg) corresponded to the dietary exposure. Direct mercury 
analysis revealed that the majority of MeHg fed mice had significantly increased [Hg] levels in 
organs, when compared with levels found in the control group. Mercury content found in liver 
tissue was higher than that found in other organs, and 21.03±1.068 mg/kg had accumulated in 
the liver of mice fed the highest dose (Fig.3-10 E) Representing a 40-fold increase compared to 
the lowest dose. Rather similar amounts were found in the pancreatic tissue of mice fed the 
highest dose, 17.74±1.320 mg/kg MeHg (Fig. 3-10 H). Furthermore, 11.06±0.5707 mg/kg and 
0.89±0.1155 mg/kg MeHg was found to accumulate in muscle and eWAT, respectively (Fig 3-
10 F/G). 
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3.11 Pancreas histology 
Effects of MeHg on apoptosis in pancreatic tissue 
A reduction of basal insulin levels in the 10 mg/kg MeHg group, and a substantial accumulation 
of Hg in pancreas led to the evaluation of the pancreatic cells. To investigate if MeHg exposure 
had an effect on pancreatic cells, mouse tissue from the HF/HS group and 10 mg/kg group, 
were stained with a fluorescent dye (Hoechst 33258) and viewed in a microscope. Images were 
assessed in order to detect apoptosis visualized as very bright nuclei (Condensed chromatin) or 
fragmented nuclei (DNA degradation), signs that the cells were preparing for programmed cell-
death. Figure 3-11 show two representative pictures from the group with the highest exposure 
to MeHg compared to the HF/HS control group. 
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Figure 3-11. Effects of MeHg on pancreatic cell nuclear morphology, stained with Hoechst 33258 and visualized 
using fluorescence microscopy. A: Images from non-supplemented HF/HS control group. B: Images from 10 
mg/kg MeHg group. Magnification of 40x and 60x is presented from both groups. 
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Initially, twenty random tissue sections from mice exposed to 10 mg/kg MeHg and HF/HS 
control was compared, and a selection of these are shown in Appendix VI: Figure A5. The 
tissue sections were thoroughly assessed and compared, but no apparent differences were 
observed in the nuclei of the pancreatic cells of mice exposed to 10 mg/kg versus. HF/HS 
control (Figure 3.11 A-B).  
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Effects of methylmercury on pancreatic islet masses 
To evaluate the potential effects of MeHg on pancreas islet mass, pancreatic tissue was stained 
with eosin/hematoxilin. Islet masses were quantified in the 10 mg/kg MeHg group versus the 
HF/HS control, by measuring the total tissue area and the total area of the islets, using Image J. 
Mice from each group were randomly selected. Langerhans islets of the pancreas in two 
representative sections are presented in fig. 3-12. 
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Figure 3-12. Pathological examination of Langerhans islets in the pancreas of one representative mice from the 
HF/HS control group and the 10 mg/kg group, visualized by staining. One 20x (scale bar = 50µm) and 40x (scale 
bar = 10 µm) magnification from each group. A: HF/HS group (n=4) B: 10 mg/kg (n=3). C: Islet mass 
quantification in the non-supplemented HF/HS versus 10 mg/kg MeHg exposure. 
Results 
 
42 
 
When assessing pancreatic tissue sections, no prominent differences were observed between 
the 10 mg/kg MeHg exposed group and non-supplemented HF/HS control (Fig. 3-12 A/B). 
Further assessment was facilitated by quantification of the islet masses of each section. No 
significant differences in the islet masses were observed, when comparing 10 mg/kg exposed 
mice, to HF/HS control (Fig. 3-12 C). Still, there was a slight decrease in islet mass in mice fed 
10 mg/kg, and variation was greater in mice exposed to 10 mg/kg (non-significantly). 
Moreover, a visual examination of the entire sample collection might have indicated lower cells 
density in the pancreatic tissue of mice exposed to a contamination pressure of 10 mg/kg versus 
non-supplemented control. A minor selection of additional images are shown in Appendix VI: 
Figure A6. 
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4 Discussion 
The purpose of this study was to investigate the potential effects of methylmercury (MeHg) on 
development of obesity and type 2 diabetes, as well as mercury accumulation in several tissues 
of the body.  Obesity have reached epidemic proportions and is closely accompanied by type 2 
diabetes and recent findings elucidate the role of environmental contaminants as metabolic and 
endocrine disruptors, potentially leading to hypoinsulinemia and type 2 diabetes (Grandjean et 
al., 2011; Sharp, 2012) Moreover, it has been reported that both organic mercury (Chen et al., 
2006a) and inorganic mercury (Chen et al., 2006c) induce pancreatic β-cell dysfunction, 
through several mechanisms impinging on insulin secretion.  
In fish and seafood, mercury mainly exists as MeHg; therefore, an obesogenic high fat/high 
sucrose (HF/HS) diet was augmented with increasing amounts of MeHg-cysteine complex. 
MeHg contents in the feed were ranging from 0.3 mg/kg -10 mg/kg. These high contamination 
pressures were used to advocate an effect in mice during a limited period. Apparent toxicity 
was not observed in any of the exposure regimens throughout the feeding trial. 
In this study, our results showed that 10 mg/kg MeHg attenuated diet-induced obesity and 
reduced basal insulin levels in mice, with no concomitant reduction in glucose tolerance, insulin 
sensitivity or glucose stimulated insulin secretion. Furthermore, we found a dose-dependent 
accumulation of mercury in organs, with the highest levels found in liver and pancreas. 
4.1 The influence of methylmercury on body weight development 
Contradictory to our assumptions that MeHg would exaggerate obesity when added to an 
obesogenic HF/HS diet, the present study shows no dose-dependent increase in obesity. In fact, 
our results indicate that MeHg has a suppressive effect on weight gain in the intermediate (1 
mg/kg) and the highest experimental dose (10mg/kg), despite being fed obesogenic HF/HS 
diets. The non-supplemented HF/HS control group gained the most weight, considering all 
groups. These differences in body weight could not be explained by alterations in total feed 
intake, because the feed intake was similar between the groups. It appears that the 10 mg/kg 
MeHg group had significantly lower feed efficiency, gaining less weight on the same amount 
of feed when compared to HF/HS control. Simultaneously, rejecting the suspicion that lower 
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weight gain was caused by depressed appetite attributable to MeHg toxicity. Reduced body 
masses were associated with lower adipose tissue mass. When assessing whole-body 
composition: the 10 mg/kg MeHg group had a significant decline in fat mass compared to 
HF/HS control. The lean mass of the animals did not decrease, confirming that the low weight 
gain was not due to food deprivation. In agreement with the modest weight gain at the highest 
exposure (10 mg/kg), the weight of visceral and subcutaneous fat depots were lower and the 
abdominal fat tended to decrease, compared to non-supplemented control. Because mice 
exhibited dissimilar feed efficiency at the different mercury exposures, we speculated whether 
this energy was eliminated through feces. The exposures that revealed a decrease in feed 
efficiency did not differ, when assessing fat absorption. Thus, indicating that energy was not 
excreted. Reduced feed efficiency in mice fed 1 mg/kg MeHg and 10 mg/kg MeHg compared 
to HF/HS, could possibly suggest an increase in metabolic activity due to MeHg exposure. 
To gain further insight, we measured the gene expression of energy demanding processes 
involved in gluconeogenesis and lipolysis. Gene expression levels did not differ among the 
groups of MeHg exposure, therefore it is not likely that energy expenditure was increased due 
to theses energy consuming processes. Considering the lack of knowledge about energy 
expenditure in this experiment, this is simply speculative. 
One can only speculate on the potential mechanisms capable of attenuating diet-induced obesity 
in diets spiked with MeHg. Kawakami et al. suggested that a reduction in adipocyte size due to 
in vivo exposures to inorganic mercury generates functional abnormalities in adipose size, 
proposing that the toxic effects of MeHg may contribute in the reduction of white adipose tissue 
depots (Kawakami et al., 2012). Other proposed mechanisms of obesity development due to 
MeHg exposure is based on the effects of MeHg on insulin. (Chen et al., 2006b). Insulin has 
three sulfur binding sites, which easily binds to mercury and might interfere in the regulation 
of blood glucose. In the present investigation, we found a decrease in basal insulin levels at the 
highest exposure, which may have prevented the obesogenic actions of the HF/HS diets. It has 
recently been suggested that high insulin levels are essential in HF-diet-induced obesity (Hao 
et al., 2012). Moreover, the fact that insulin-receptor knockout mice are protected from diet- 
induced obesity, indicate that insulin signaling in adipocytes is essential for obesity 
development (Bluher et al., 2002). MeHg potentially mediates its effects on energy metabolism 
by altering intracellular calcium concentrations in pancreatic β-cells (Zhou et al., 1998). 
Numerous mechanisms have been suggested in trying to explain the possible association 
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between obesity and contaminants; mainly through interruption of energy homeostasis, glucose 
and lipid metabolism and regulation of adipogenesis. (Kelishadi et al., 2013; Newbold, 2010). 
Nevertheless, exact target tissues are unknown; adipose tissues and endocrine cells 
communicates with endocrine signals from many organs which may involve brain, liver, gut 
and pancreas. Nonetheless, these reviews have not targeted MeHg in particular, but might give 
an indication of potential explanations for how MeHg might impinge on weight development 
and metabolism. 
4.2 The effects of methylmercury on metabolic processes 
In the present study, MeHg was not associated with obesity. I order to investigate the exerted 
effects on metabolic regulation, a glucose tolerance test and insulin tolerance test was 
performed, and some genes affecting these processes were explored.  
Our results displayed a decrease in glucose tolerance among mice fed the lowest exposure dose 
(0.3 mg/kg MeHg). Fasted glucose levels were rather similar across groups, indicating no state 
of hyperglycemia, found in type 2 diabetes. In addition, 0.3 mg/kg MeHg fed mice remained 
insulin sensitive, probably coincident with the moderate weight gain. In fact, all groups 
remained insulin sensitive, regardless of contamination pressures, suggesting no negative 
association between MeHg and insulin secretion. 
MeHg significantly reduced basal insulin levels in mice fed 10 mg/kg, compared to non-
supplemented HF/HS. However, no significant alterations were detected in glucose stimulated 
insulin secretion among the groups. Unexpectedly, basal blood glucose was not elevated due to 
reduced basal insulin levels in the 10 mg/kg MeHg group. The latter did not develop insulin 
resistance and according to HOMA-IR calculations, 10 mg/kg methyl mercury fed mice were 
highly insulin sensitive. This is in line with the fact that 10 mg/kg exposed mice remained lean. 
Regardless of the complexity of these interactions, it is not to be dismissed that a decline in 
basal glucose levels, might indicate a reduced ability of the β-cells to produce insulin. 
Pathological alterations in pancreas capable of inducing endocrine disturbances was already 
described in 1977, when Takeuchi et al. found perturbations in the epithelium of pancreatic islet 
cells in autopsy cases of Minamata disease (Takeuchi T and Eto K, 1977). Although not 
significant, our results displayed a rather consistent pattern in glucose stimulated insulin 
secretion across the groups, in which insulin levels increased from 0.3 mg/kg to 3 mg/kg 
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followed by a decline at the highest exposure regimens. The intermediate-exposures (1 mg/kg 
and 3 mg/kg) tended to increase glucose stimulated insulin secretion. It has been suggested that 
some contaminants exert a low dose stimulation, high dose inhibition displaying an inverted u-
shaped dose response. (Calabrese and Baldwin, 2003). Thus, acting to improve physiological 
parameters at low doses, followed by an deterioration at higher exposures. In addition to the 
possibility that MeHg could act stimulatory at low doses, and inhibitory at high doses, some 
toxicological studies have demonstrated non-monotonic dose responses (Welshons et al., 2003). 
Recently, Chang et al. found  that dioxin exposure was associated with a slight monotonic 
increase in insulin resistance in Taiwanese living in a highly polluted area (Chang et al., 2011). 
It might not be possible to predict responses in low dose exposures, based on exposures in a 
high range, underlining the fact that dose responses are ambiguous (Newbold, 2010). Further, 
our finding that mice receiving the lowest dose (0.3 mg/kg) exhibited glucose intolerance might 
indicate that the effects of MeHg differ in the low region exposures, compared to higher. 
Subsequently raising the question whether even lower doses could trigger more adverse effects 
on different metabolic markers. For instance, Chen et al. found that low doses of MeHg was 
capable of modifying glucose tolerance and insulin secretion after 4 weeks in vitro. (Chen et 
al., 2006c).  
In the current experiment, MeHg was not associated with insulin resistance. Insulin resistance 
is closely related to obesity, therefore the modest weight gain in all groups might partly explain 
why the mice remained insulin sensitive (Xu et al., 2003). However, we  measured whole body 
non-specific insulin sensitivity, and thus, indications about the insulin sensitivity of individual 
organs are restricted. Further, we do not know if a pro-longed exposure, at the same or other 
doses, would have triggered insulin resistance, and glucose intolerance. An increase in adipose 
tissue, would possibly have lead to increased levels of free fatty acids which in turn might lead 
to resistance to insulin signaling in liver and muscle (Yu et al., 2002). Recently, Yamamoto et 
al. found that body fat gain in mice with type 2 diabetes mellitus increased the toxicity of MeHg 
compared to lean non-diabetic C57BL/6 mice (Yamamoto et al., 2013). We can only speculate 
if we had seen more adverse effects of MeHg if the mice were fat before the implementation of 
MeHg.  
Liver is one of the target organs of MeHg and at the same time has major impact on metabolic 
processes, therefore very relevant when assessing obesity and diabetes. The liver masses did 
not differ between the treatment groups, displaying no immediate pathological alterations in 
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response to MeHg supplemented HF/HS diets. Further, it was evident that liver had 
accumulated the highest amounts of MeHg, among the organs that were analysed. MeHg is 
known to accumulate extensively in the liver, and among other organs like the brain and kidneys 
(Bridges and Zalups, 2010; Rodrigues et al., 2010). Interestingly, Roos et al. found that 
exposures to MeHg-cys complex substantially increased accumulation in liver, when compared 
to MeHg alone (Roos et al., 2010). Due to the high accumulation in liver, hepatic gene 
expression was explored. Assessments of a selection of genes, did not display a transparent 
relationship between contamination pressure and gene expression in liver. There were no 
differences in genes involved in anabolic processes nor energy expending processes in the liver. 
This might be an indication that accumulation  is not predicative of the metabolic functions of 
the liver. Based on these results, it is not likely that the reduction in basal insulin levels was due 
to alterations of gene expression in liver.  
4.3 Methylmercury accumulation and pancreatic function 
In the current investigation, MeHg was associated with a reduction in basal insulin secretion in 
response to a contamination pressure of 10 mg/kg. Based on this finding we speculate if MeHg 
could have negative effects on the ability of pancreas to secrete insulin.  
Pancreas masses did not differ among the treatment groups, displaying no obvious pathological 
change in the organ mass due to MeHg exposure. In line with others that have investigated 
accumulation in liver, our results show that the hepatic burdens are highest when exposed to 
MeHg-cysteine complex, as opposed to MeHg alone (Roos et al., 2010). It has been suggested 
that the high accumulation might be related to the protein metabolic properties of the liver, 
receiving amino acids from the gastrointestinal tract and other organs (Adachi, 2006). When 
comparing the accumulation of MeHg in the different organs, it was evident that pancreas 
accumulated nearly as much as liver, whereas muscle displayed only half of the burden found 
in liver and pancreas. Only small amounts accumulated in eWAT, similar to what has been 
found in other studies (Nielsen, 1992; Yamamoto et al., 2013). Overall, the investigated organs 
displayed an increase in MeHg in which the highest exposure yielded the highest burden.  
Surprisingly, we found that pancreas accumulated high concentrations of MeHg. To our 
knowledge, investigations on the cumulative properties of MeHg in mice pancreas is restricted. 
However, Yamamoto et al. recently explored the total mercury concentrations in pancreas of 
C57BL/6 mice and diabetic KK-AY mice after MeHg administration through oral gavage 
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(Yamamoto et al., 2013). In their study, kidneys accumulate the most MeHg, followed by 
pancreas and liver. Additionally, the obese diabetic KK-AY mice had much greater 
accumulation in pancreas and liver than the lean non-diabetic C57BL/6 control mice, 
suggesting that body weight gain might be a predictor for MeHg susceptibility and individual 
differences in response to contamination. Whereas the current experiment added MeHg-cys to 
feed, Yamamoto et al. administered MeHg without a food matrix. Given that the route of 
exposure differs from the present investigation, we speculate if uptake and distribution may 
differ. There are many factors conflicting the basis for comparison between studies; 
emphasizing the importance of mimicking the normal human exposure route and relevant 
mercury species, to obtain a more realistic view on accumulation in target organs.  
The accumulation of MeHg in target organs could possibly reflect the burdens observed, but is 
not predicative of a pathological outcome. Considering that pancreas is the organ responsible 
for insulin secretion, it is also a representative target organ for diabetes. Therefore, we explored 
the pancreatic tissue of mice at the highest exposure level (10 mg/kg), through histological 
methods. We found no signs of apoptosis when comparing the non-supplemented HF/HS 
control group and 10 mg/kg MeHg exposed mice. We cannot exclude the possibility that 
apoptosis occurred in the pancreatic tissues based on these observations alone. Although we 
made no observations on condensed nuclei, apoptosis may have occurred in the cells of 
pancreas. If we had used early apoptotic markers to detect apoptosis, this could have provided 
knowledge in regards of the regulation of apoptotic proteins. Thus highlighting that the current 
observations are by no means conclusive in regards of MeHg effect on cells of the pancreas. 
Previous studies have demonstrated the ability of MeHg to induce β-cell dysfunction and cell 
apoptosis through an oxidative stress pathway in mice. The same group of scientists reported 
that activation of the PI3K- pathway caused β-cell dysfunction through an AKT signaling 
pathway and thereby decreasing insulin secretion, suggesting that exposure to mercury may be 
a risk factor for diabetes (Chen et al., 2006b; Chen et al., 2006c; Chen et al., 2010). An 
experiment in rats have reported that a single injection of MeHg was capable of damaging 
pancreatic islets, and that repeated injections triggered high glucose levels (Shigenaga, 1976). 
To gain further insight on the potential interferences of MeHg in pancreatic tissues, we 
investigated the islets of pancreas. We observed no apparent morphological alterations in the 
islets, and the different sections displayed no obvious difference in islet mass, comparing 1 
mg/kg, 10 mg/kg and the HF/HS control group. Further we quantified the islet mass in randomly 
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selected tissues within the HF/HS control group and 10 mg/kg.  Although non-significant, islet 
mass was slightly lower in the 10 mg/kg group and the variation within the this group was 
slightly higher, compared to HF/HS control. This might be an indication that some mice 
responded to the exposures, whereas others did not. Further examinations of all sections 
indicated that there might be a slight decrease in cell density in islets of the pancreas at the 
highest exposure regimen, compared to non-supplemented HF/HS control.  
In human studies, the potential role of MeHg in development of diabetes have been elucidated 
and findings are contradictory. A cross sectional study from the Faroese population reported 
that exposures to contaminants, impaired insulin secretion in 70 year olds, which is an important 
part of type 2 diabetes pathogenesis (a population with high consumption of pilot whale) 
(Grandjean et al., 2011). Findings from the Coronary Artery Risk Development in Young 
Adults (CARDIA) study, recently reported an association between high methylmercury 
exposures in young adulthood and higher risk of diabetes later in life (He et al., 2013). In 1995 
a retrospective study suggested that an increase in incidence diabetes seen in Minamata disease 
might be explained by high methylmercury exposures (Uchino et al., 1995). However, 
conflicting evidence was recently reported from two separate large prospective cohorts, 
reporting no adverse effects of MeHg on development of diabetes. (Mozaffarian et al., 2013) 
Equally, an epidemiological study in a population living in a MeHg polluted area showed no 
increase in diabetes mellitus (Futatsuka et al., 1996). Regardless, more research is required to 
elucidate the role of MeHg on type 2 diabetes.  
4.4 Human relevance 
Fish and seafood is an important part of a healthy diet because it contains many beneficial 
nutrients (Strain et al., 2008; VKM, 2006). Some nutrients in seafood may have ameliorating 
effects on MeHg toxicity, among them selenium and Omega 3 (Folven et al., 2009; Nostbakken 
et al., 2012). In the present investigation the beneficial nutrients in fish and seafood was not 
accounted for, and a holistic risk-benefit evaluation is required to assess the effects of MeHg 
through seafood consumption. The exposures in the present experiment is not comparable to 
human consumption because the mice were chronically exposed to MeHg through every meal, 
whereas humans eat a variety of foods. Although, the lowest dose (0.3 mg/kg) is similar to that 
found in some freshwater fish (pike, trout, perch) and 1-3 mg/kg might be found in some 
predatory fish (Greenland halibut, tuna) and deep water fish species (tusk) in particular areas. 
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However, the consumption of these species are considered low, although not excluding the fact 
that some groups in the population might consume these species at a regular basis. 
4.5 The animal model 
The mice model is frequently used in scientific research because of their similarity to humans 
in terms of genetics, anatomy and physiology. Moreover, the given opportunity to control an 
experiment is of great value in achieving scientifically valid research. However, caution must 
be taken in translating the outcome to humans. Whereas features of the inbred strain is desirable 
when controlling the experiment, inbreeding gives less genetic variation somewhat 
compromising human resemblance. Thus, underlining the importance of restriction when 
generalizing findings.  
The mouse model is valuable in providing insights into aspects of toxicity otherwise impossible 
to investigate. C57BL/6 is an appropriate model when assessing obesity and diabetes, however, 
there are several mouse models that might be more appropriate when assessing contaminants 
like MeHg. In the current investigation, C57BL/6 mice demonstrated profound endurance 
against the high dose exposures. Other mice-strains might be more susceptible to MeHg and 
might exhibit toxic responses much earlier. BALBc is commonly used in toxicology studies, 
and a recent study using KK-AY mice demonstrated high susceptibility to MeHg 
exposure(Yamamoto et al., 2013).  
4.6 Methodology 
 
Feed production  
Obesity development was evaluated on the basis of a 13 week feeding trial. Production of feed 
was part of the laboratory training. Due to the fact that the feed production consisted into the 
feeding trial and consisted of several batches, the consistency of the feed was varying in the 
first weeks of feeding. This might have resulted in a weight gain advantage for the mice 
receiving a consistent diet, and a stressor for the counterpart. Diets were analyzed for MeHg, 
fat, protein, displaying similar contents. For future experiments, it would be beneficial to 
prepare and analyze the diets prior to the feeding trial, to ensure a homogenous feed 
accessibility for the animals at all times. Since feed intake was comparable among the groups, 
it is not likely that this had an impact on the outcome of our experiment. Based on experience 
from parallel experiments, the ability to induce obesity might also be dependent on the physical 
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form of the diet; Pellet vs. powdered feed. Findings from a recent study in C57BL/6 mice 
showed a greater increase in body weight when fed a powdered diet, than mice fed the pelleted 
diets (Yan et al., 2011).  
 
 Conclusions 
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5 Conclusions 
In vivo, chronic exposures to progressive (0.3 mg/kg, 1 mg/kg, 3 mg/kg and 10 mg/kg) 
methylmercury-cysteine concentrations, supplemented to an obesogenic high fat/high sucrose 
diet, did not induce obesity development in C57BL/6 mice, however: 
 The highest MeHg exposure (10 mg/kg) attenuated diet-induced obesity and reduced 
basal insulin secretion. 
 Mercury accumulated dose-dependently in several organs, with the highest levels 
accumulated in liver and pancreas. 
 MeHg induced a modest decline in glucose tolerance at the lowest exposure regimen 
(0.3 MeHg) but was not associated with reduced insulin sensitivity or reduced glucose 
stimulated insulin secretion. 
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5.1 Future perspectives 
Due to the accumulation of mercury in pancreas and reduced basal insulin secretion at the 
highest exposure, it would be interesting to: 
 Locate the sites for accumulation, through mercury specific staining in pancreatic tissue 
and investigate if there is a selective accumulation in pancreatic β-cells. 
 Isolate primary islets and expose to methylmercury to investigate the effect on glucose 
stimulated insulin secretion 
 Investigate the effects of methylmercury in other background diets, with pro-longed 
exposure, and explore the effects of lower methylmercury doses. 
 Further, investigate if methylmercury induces apoptosis in pancreatic cells. For instance 
by investigating early apoptotic markers.
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54 
 
6 References 
Adachi, T. (2006). Characteristic effects of L-methionine on tissue distribution of 
methylmercury in mice. Journal of Health Science, 174-172. 
Allen, J.W., Shanker, G., and Aschner, M. (2001). Methylmercury inhibits the in vitro uptake 
of the glutathione precursor, cystine, in astrocytes, but not in neurons. Brain Research 894, 131-
140. 
Andrikopoulos, S., Blair, A.R., Deluca, N., Fam, B.C., and Proietto, J. (2008). Evaluating the 
glucose tolerance test in mice. Am J Physiol Endocrinol Metab 295, E1323-1332. 
Atchison, W.D., and Hare, M.F. (1994). Mechanisms of methylmercury-induced neurotoxicity. 
FASEB J 8, 622-629. 
ATSDR (1999). ToxFAQsTM for Mercury (Atlanta). 
Bakir, F., Damluji, S.F., Amin-Zaki, L., Murtadha, M., Khalidi, A., al-Rawi, N.Y., Tikriti, S., 
Dahahir, H.I., Clarkson, T.W., Smith, J.C., et al. (1973). Methylmercury poisoning in Iraq. 
Science 181, 230-241. 
Betty L. Black, J.C., E.J. Eisen, Ann E. Petro, Christopher L. Edwards, Richard S. Surwit, 
(1998). Differential effects of fat and sucrose on body composition in AJ and C57BL/6 mice. 
Metabolism Volume 47, 1354-1359 
Bluher, M., Michael, M.D., Peroni, O.D., Ueki, K., Carter, N., Kahn, B.B., and Kahn, C.R. 
(2002). Adipose tissue selective insulin receptor knockout protects against obesity and obesity-
related glucose intolerance. Dev Cell 3, 25-38. 
Bray, G.A. (2004). Medical Consequences of Obesity. The Journal of Clinical Endocrinology 
& Metabolism 89, 2583-2589. 
Bridges, C.C., and Zalups, R.K. (2010). Transport of inorganic mercury and methylmercury in 
target tissues and organs. J Toxicol Environ Health B Crit Rev 13, 385-410. 
Calabrese, E.J., and Baldwin, L.A. (2003). Hormesis: the dose-response revolution. Annu Rev 
Pharmacol Toxicol 43, 175-197. 
Ceccatelli, S., Dare, E., and Moors, M. (2010). Methylmercury-induced neurotoxicity and 
apoptosis. Chem Biol Interact 188, 301-308. 
Chang, J.W., Chen, H.L., Su, H.J., Liao, P.C., Guo, H.R., and Lee, C.C. (2011). Simultaneous 
exposure of non-diabetics to high levels of dioxins and mercury increases their risk of insulin 
resistance. J Hazard Mater 185, 749-755. 
References 
 
55 
 
Chen, Y.W., Huang, C.F., Tsai, K.S., Yang, R.S., Yen, C.C., Yang, C.Y., Lin-Shiau, S.Y., and 
Liu, S.H. (2006a). Methylmercury induces pancreatic beta-cell apoptosis and dysfunction. 
Chem Res Toxicol 19, 1080-1085. 
Chen, Y.W., Huang, C.F., Tsai, K.S., Yang, R.S., Yen, C.C., Yang, C.Y., Lin-Shiau, S.Y., and 
Liu, S.H. (2006b). Methylmercury Induces Pancreatic β-Cell Apoptosis and Dysfunction. 
Chemical Research in Toxicology 19, 1080-1085. 
Chen, Y.W., Huang, C.F., Tsai, K.S., Yang, R.S., Yen, C.C., Yang, C.Y., Lin-Shiau, S.Y., and 
Liu, S.H. (2006c). The role of phosphoinositide 3-kinase/Akt signaling in low-dose mercury-
induced mouse pancreatic beta-cell dysfunction in vitro and in vivo. Diabetes 55, 1614-1624. 
Chen, Y.W., Huang, C.F., Yang, C.Y., Yen, C.C., Tsai, K.S., and Liu, S.H. (2010). Inorganic 
mercury causes pancreatic beta-cell death via the oxidative stress-induced apoptotic and 
necrotic pathways. Toxicol Appl Pharmacol 243, 323-331. 
Chen, Y.W., Yang, C.Y., Huang, C.F., Hung, D.Z., Leung, Y.M., and Liu, S.H. (2009). Heavy 
metals, islet function and diabetes development. Islets 1, 169-176. 
Clarkson, T.W. (1972). The pharmacology of mercury compounds. Annu Rev Pharmacol 12, 
375-406. 
Clarkson, T.W., L. Friberg, G. Nordberg, and P.R. Sager (1988). Biological Monitoring of 
Toxic Metals. . 
Clarkson, T.W., and Magos, L. (2006). The toxicology of mercury and its chemical compounds. 
Crit Rev Toxicol 36, 609-662. 
EFSA (2012). Panel on Contaminants in the Food Chain (CONTAM). Scientific Opinion on 
the risk for public health related to the presence of mercury and methylmercury in food. (EFSA 
Journal 2012). 
Eto, K. (1997). Pathology of Minamata disease. Toxicol Pathol 25, 614-623. 
Federico, A., D'Aiuto, E., Borriello, F., Barra, G., Gravina, A.G., Romano, M., and De Palma, 
R. (2010). Fat: a matter of disturbance for the immune system. World J Gastroenterol 16, 4762-
4772. 
Ferrannini, E., Gastaldelli, A., Miyazaki, Y., Matsuda, M., Mari, A., and DeFronzo, R.A. 
(2005). β-Cell Function in Subjects Spanning the Range from Normal Glucose Tolerance to 
Overt Diabetes: A New Analysis. The Journal of Clinical Endocrinology & Metabolism 90, 
493-500. 
References 
 
56 
 
Folven, K.I., Glover, C.N., Malde, M.K., and Lundebye, A.K. (2009). Does selenium modify 
neurobehavioural impacts of developmental methylmercury exposure in mice? Environ Toxicol 
Pharmacol 28, 111-119. 
Futatsuka, M., Kitano, T., and Wakamiya, J. (1996). An epidemiological study on diabetes 
mellitus in the population living in a methyl mercury polluted area. J Epidemiol 6, 204-208. 
Graff, R.D., Falconer, M.M., Brown, D.L., and Reuhl, K.R. (1997). Altered sensitivity of 
posttranslationally modified microtubules to methylmercury in differentiating embryonal 
carcinoma-derived neurons. Toxicol Appl Pharmacol 144, 215-224. 
Grandjean, P., Henriksen, J.E., Choi, A.L., Petersen, M.S., Dalgard, C., Nielsen, F., and Weihe, 
P. (2011). Marine food pollutants as a risk factor for hypoinsulinemia and type 2 diabetes. 
Epidemiology 22, 410-417. 
Hao, Q., Lillefosse, H.H., Fjaere, E., Myrmel, L.S., Midtbo, L.K., Jarlsby, R.H., Ma, T., Jia, B., 
Petersen, R.K., Sonne, S.B., et al. (2012). High-glycemic index carbohydrates abrogate the 
antiobesity effect of fish oil in mice. Am J Physiol Endocrinol Metab 302, E1097-1112. 
He, K., Xun, P., Liu, K., Morris, S., Reis, J., and Guallar, E. (2013). Mercury exposure in young 
adulthood and incidence of diabetes later in life: the CARDIA Trace Element Study. Diabetes 
Care 36, 1584-1589. 
Hirayama, K. (1985). Effects of combined administration of thiol compounds and 
methylmercury chloride on mercury distribution in rats. Biochem Pharmacol 34, 2030-2032. 
Hirayama, K., Yasutake, A., and Adachi, T. (1991). Mechanism for Renal Handling of 
Methylmercury. In Advances in Mercury Toxicology, T. Suzuki, N. Imura, and T. Clarkson, 
eds. (Springer US), pp. 121-134. 
Jurgens, C.A., Toukatly, M.N., Fligner, C.L., Udayasankar, J., Subramanian, S.L., Zraika, S., 
Aston-Mourney, K., Carr, D.B., Westermark, P., Westermark, G.T., et al. (2011). beta-cell loss 
and beta-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition. Am J 
Pathol 178, 2632-2640. 
Kahn, S.E., Cooper, M.E., and Del Prato, S. (2014). Pathophysiology and treatment of type 2 
diabetes: perspectives on the past, present, and future. Lancet 383, 1068-1083. 
Kawakami, T., Hanao, N., Nishiyama, K., Kadota, Y., Inoue, M., Sato, M., and Suzuki, S. 
(2012). Differential effects of cobalt and mercury on lipid metabolism in the white adipose 
tissue of high-fat diet-induced obesity mice. Toxicol Appl Pharmacol 258, 32-42. 
Kelishadi, R., Poursafa, P., and Jamshidi, F. (2013). Role of environmental chemicals in 
obesity: a systematic review on the current evidence. J Environ Public Health 2013, 896789. 
References 
 
57 
 
Kershaw, T.G., Clarkson, T.W., and Dhahir, P.H. (1980). The relationship between blood levels 
and dose of methylmercury in man. Arch Environ Health 35, 28-36. 
Lancet (2011). The global obesity pandemic: shaped by global drivers and local environments. 
wwwthelancetcom Vol 378. 
Layden, T.B., Durai, V., and William., L.L. (2010). G-Protein-Coupled Receptors, Pancreatic 
Islets and Diabetes. Nature education. 
Leto, D., and Saltiel, A.R. (2012). Regulation of glucose transport by insulin: traffic control of 
GLUT4. Nat Rev Mol Cell Biol 13, 383-396. 
Lowell, B.B., and Shulman, G.I. (2005). Mitochondrial dysfunction and type 2 diabetes. . 
Science, 384-387. 
MacDonald, M.J., and Fahien, L.A. (1990). Insulin release in pancreatic islets by a glycolytic 
and a Krebs cycle intermediate: contrasting patterns of glyceraldehyde phosphate and succinate. 
Arch Biochem Biophys 279, 104-108. 
Mason, R.P., Rolfhus, K.R., and Fitzgerald, W.F. (1995). Methylated and elemental mercury 
cycling in surface and deep ocean waters of the North Atlantic. Water Air Soil Pollut 80, 665-
677. 
McCarthy, M.I. (2010). Genomics, Type 2 Diabetes, and Obesity. New England Journal of 
Medicine 363, 2339-2350. 
Morel, F., Kraepiel, A., and Amyot, M. (1998). The chemical cycle and bioaccumulation of 
mercury. Annual Review of Ecology and Systematics 29, 543-566. 
Mozaffarian, D., Shi, P., Morris, J.S., Grandjean, P., Siscovick, D.S., Spiegelman, D., and Hu, 
F.B. (2013). Methylmercury exposure and incident diabetes in U.S. men and women in two 
prospective cohorts. Diabetes Care 36, 3578-3584. 
Måge, A., Bjelland, O., Olsvik, P., Nilsen, B., and Julshamn, K. (2011). Miljøgifter i fisk og 
fiskevarer 2011: Kvikksølv i djupvassfisk og skaldyr frå Hardangerfjorden samt miljøgifter i 
marine oljer 
2012 (Bergen, Nasjonalt institutt for ernærings- og sjømatforskning (NIFES)). 
National Research Counsil (2011). Guide for the Care and Use of Laboratory Animals: Eighth 
Edition (The National Academies Press). 
Newbold, R.R. (2010). Impact of environmental endocrine disrupting chemicals on the 
development of obesity. Hormones (Athens) 9, 206-217. 
Nielsen, J.B. (1992). Toxicokinetics of mercuric chloride and methylmercuric chloride in mice. 
J Toxicol Environ Health 37, 85-122. 
References 
 
58 
 
Nostbakken, O.J., Bredal, I.L., Olsvik, P.A., Huang, T.S., and Torstensen, B.E. (2012). Effect 
of marine omega 3 fatty acids on methylmercury-induced toxicity in fish and mammalian cells 
in vitro. J Biomed Biotechnol 2012, 417652. 
Petro, A.E., Cotter, J., Cooper, D.A., Peters, J.C., Surwit, S.J., and Surwit, R.S. (2004). Fat, 
carbohydrate, and calories in the development of diabetes and obesity in the C57BL/6J mouse. 
Metabolism 53, 454-457. 
Poitout, V., Amyot, J., Semache, M., Zarrouki, B., Hagman, D., and Fontes, G. (2010). 
Glucolipotoxicity of the pancreatic beta cell. Biochim Biophys Acta 1801, 289-298. 
Quinn, P.G., and Yeagley, D. (2005). Insulin regulation of PEPCK gene expression: a model 
for rapid and reversible modulation. Curr Drug Targets Immune Endocr Metabol Disord 5, 423-
437. 
Rahier, J., Guiot, Y., Goebbels, R.M., Sempoux, C., and Henquin, J.C. (2008). Pancreatic beta-
cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab 10 Suppl 4, 32-42. 
Rodrigues, J.L., Serpeloni, J.M., Batista, B.L., Souza, S.S., and Barbosa, F., Jr. (2010). 
Identification and distribution of mercury species in rat tissues following administration of 
thimerosal or methylmercury. Arch Toxicol 84, 891-896. 
Rolo, A.P., and Palmeira, C.M. (2006). Diabetes and mitochondrial function: role of 
hyperglycemia and oxidative stress. Toxicol Appl Pharmacol 212, 167-178. 
Rooney, J.P.K. (2007). The role of thiols, dithiols, nutritional factors and interacting ligands in 
the toxicology of mercury. Toxicology 234, 145-156. 
Roos, D.H., Puntel, R.L., Lugokenski, T.H., Ineu, R.P., Bohrer, D., Burger, M.E., Franco, J.L., 
Farina, M., Aschner, M., Rocha, J.B., et al. (2010). Complex methylmercury-cysteine alters 
mercury accumulation in different tissues of mice. Basic Clin Pharmacol Toxicol 107, 789-792. 
Saltiel, A.R., and Kahn, C.R. (2001). Insulin signalling and the regulation of glucose and lipid 
metabolism. Nature 414, 799-806. 
Sarafian, T., and Verity, M.A. (1991). Oxidative mechanisms underlying methyl mercury 
neurotoxicity. Int J Dev Neurosci 9, 147-153. 
Schaefer, J.K., Rocks, S.S., Zheng, W., Liang, L., Gu, B., and Morel, F.M. (2011). Active 
transport, substrate specificity, and methylation of Hg(II) in anaerobic bacteria. Proc Natl Acad 
Sci U S A 108, 8714-8719. 
Sharp, D. (2012). Environmental toxins, a potential risk factor for diabetes among canadian 
aborginals. International Journal of Circumpolar Health 68. 
References 
 
59 
 
Shigenaga, K. (1976). Pancreatic islet injury induced by methyl mercuric chloride light and 
electron microscopic studies. Kumamoto Med J 29, 67-81. 
Strain, J.J., Davidson, P.W., Bonham, M.P., Duffy, E.M., Stokes-Riner, A., Thurston, S.W., 
Wallace, J.M., Robson, P.J., Shamlaye, C.F., Georger, L.A., et al. (2008). Associations of 
maternal long-chain polyunsaturated fatty acids, methyl mercury, and infant development in 
the Seychelles Child Development Nutrition Study. Neurotoxicology 29, 776-782. 
Surwit, R.S., Feinglos, M.N., Rodin, J., Sutherland, A., Petro, A.E., Opara, E.C., Kuhn, C.M., 
and Rebuffe-Scrive, M. (1995). Differential effects of fat and sucrose on the development of 
obesity and diabetes in C57BL/6J and AJ mice. Metabolism 44, 645-651. 
Takeuchi T, and Eto K (1977). Patology and pathogenesis of Minamata disease. Kodansha 
LTD, 103-141. 
Tsubaki, T. (1967). Outbreak of intoxication by organic compounds in Niigata Prefecture Jpn 
J Med Sci Biol. 
Uchino, M., Tanaka, Y., Ando, Y., Yonehara, T., Hara, A., Mishima, I., Okajima, T., and Ando, 
M. (1995). Neurologic features of chronic minamata disease (organic mercury poisoning) and 
incidence of complications with aging. J Environ Sci Health B 30, 699-715. 
VKM (2006). Norwegian Scientific Commitee for Food Safety. A comprehensive assessment 
of fish and other seafood in the Norwegian diet. 
Welshons, W.V., Thayer, K.A., Judy, B.M., Taylor, J.A., Curran, E.M., and vom Saal, F.S. 
(2003). Large effects from small exposures. I. Mechanisms for endocrine-disrupting chemicals 
with estrogenic activity. Environ Health Perspect 111, 994-1006. 
WHO (2000). Obesity: preventing and managing the global epidemic. (Geneva). 
WHO (2008). Guidance for Identifying Populations at Risk from Mercury Exposure (Geneva). 
WHO (2011). Global status report on noncommunicable diseases 2010, W.h. oranization, ed., 
pp. 176. 
Xu, H., Barnes, G.T., Yang, Q., Tan, G., Yang, D., Chou, C.J., Sole, J., Nichols, A., Ross, J.S., 
Tartaglia, L.A., et al. (2003). Chronic inflammation in fat plays a crucial role in the 
development of obesity-related insulin resistance. J Clin Invest 112, 1821-1830. 
Yamamoto, M., Yanagisawa, R., Motomura, E., Nakamura, M., Sakamoto, M., Takeya, M., 
and Eto, K. (2013). Increased methylmercury toxicity related to obesity in diabetic KK-Ay 
mice. J Appl Toxicol. 
References 
 
60 
 
Yan, L., Combs, G.F., Jr., DeMars, L.C., and Johnson, L.K. (2011). Effects of the physical form 
of the diet on food intake, growth, and body composition changes in mice. J Am Assoc Lab 
Anim Sci 50, 488-494. 
Yasutake, A., Nakano, A., Miyamoto, K., and Eto, K. (1997). Chronic effects of methylmercury 
in rats. I. Biochemical aspects. Tohoku J Exp Med 182, 185-196. 
Yu, C., Chen, Y., Cline, G.W., Zhang, D., Zong, H., Wang, Y., Bergeron, R., Kim, J.K., 
Cushman, S.W., Cooney, G.J., et al. (2002). Mechanism by which fatty acids inhibit insulin 
activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase 
activity in muscle. J Biol Chem 277, 50230-50236. 
Zhou, Y.P., Teng, D., Dralyuk, F., Ostrega, D., Roe, M.W., Philipson, L., and Polonsky, K.S. 
(1998). Apoptosis in insulin-secreting cells. Evidence for the role of intracellular Ca2+ stores 
and arachidonic acid metabolism. J Clin Invest 101, 1623-1632. 
 
 Appendix 
  
61 
 
I. APPENDIX – DIET COMPOSITION  
Table A1. Feed preparation recipe and reported values from the laboratory at NIFES. Units of measurements are 
presented individually, displaying ingredients (g/kg), contaminant pressure (mg/kg), the energy content (kcal/g) 
and macronutrient composition (%). 
 
 
Table A2. List of suppliers for dietary components 
Ingredients Supplier 
Vitamin mix Special Diets Services 
Mineral mix Special Diets Services 
Cellulose Apotekproduksjon A/S 
Choline Hydrogentartrate Merck 
L-cystine Sigma Life Science 
T-butylhydrochinon Aldrich 
Sucrose (powdered sugar) Eldorado 
Dextrin Hoff 
Casein Sigma Life Science 
Corn oil Eldorado 
MeHg-cystein   
L-cystein hydrochloride monohydrate MW (175,6 g/mol) Sigma Life Science 
Rectified alcohol Arcus kjemi, Norway 
Methylmercury solution Sigma Life Science 
RNase free ddH2O MiliQ Millipore, USA 
 
 
Low fat High fat/ High sugar HF/HS 0.3 mg/kg HF/HS 1 mg/kg HF/HS 3 mg/kg HF/HS 10 mg/kg
(g/kg) (g/kg) (g/kg) (g/kg) (g/kg) (g/kg)
Vitamin mix 10 10 10 10 10 10
Mineral mix 35 35 35 35 35 35
Cellulose 50 50 50 50 50 50
Choline Hydrogentartrate 2,5 2,5 2,5 2,5 2,5 2,5
L-cystine 3 3 3 3 3 3
T-butylhydrochinon 0,014 0,014 0,014 0,014 0,014 0,014
Sucrose (powdered sugar) 90 438 438 438 438 438
Dextrin 540 12 12 12 12 12
Casein 200 200 200 200 200 200
Corn oil 70 250 250 250 250 250
1000,5 1000,5 1000,5 1000,5 1000,5 1000,5
- - 0,3* 1* 3* 10*
Kcal/g 3,95 4,85 4,85 4,85 4,85 4,85
*Carohydrates (%) 630 450 450 450 450 450
Reported value* Protein (%) 190 180 175 180 175 180
Fat (%) 63 240 240 240 240 240
MeHg-Cys (mg/kg) - - 0,54 0,83 2,4 8,29
Kcal/g 4,45 4,50 5,30 5,30 5,25 5,20
Contaminant MeHg-cys (mg/kg)*
Diet composition
Ingredients
Basemix
Individual-Diet
Total amount (kg)
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Table A3. Methylmercury concentrations (ml) and ethanol/water solutions (ml) for each experimental diet. 
Diet 50:50 Ethanol/Water solution 
(ml) 
MeHg-Cys solution (ml) 
0 mg/kg (ˣ2) 60   
0,3 mg/kg 58,3 1,68 
1 mg/kg 54 6 
3 mg/kg 43,2 16,8 
10 mg/kg 4,2 55,8 
 
 
II. APPENDIX - ELISA 
 
Table A4. Insulin Mouse ELISA kit. 
Product 
Supplier 
Insulin Mouse Ultrasensitive ELISA Kit DRG Instruments GmbH, Germany 
Coated plate DRG Instruments GmbH, Germany 
Calibrator 0 (1 vial) DRG Instruments GmbH, Germany 
Calibrator 1,2,3,4,5 (5 vials) DRG Instruments GmbH, Germany 
Enzyme Conjugate 11X (1 vial) DRG Instruments GmbH, Germany 
Enzyme Conjugate buffer (1 vial) DRG Instruments GmbH, Germany 
Wash buffer (1 bottle) DRG Instruments GmbH, Germany 
Substrate TMB (1 bottle) DRG Instruments GmbH, Germany 
Stop solution (1 vial) DRG Instruments GmbH, Germany 
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III. APPENDIX – QUANTITATIVE POLYMERASE CHAIN REACTION 
 
Table A5. Reagents and chemicals used during homogenization and RNA extraction 
Product 
Supplier 
Rnase ZAP Sigma, USA 
Trizol Invitrogen, Norge 
Chloroform VWR international, USA 
Isopropanol Arcus kjemi, Norway 
Ethanol Arcus kjemi, Norway 
DEPC Sigma, USA 
RNase free ddH2O MiliQ Biocel apparatus, Nifes 
  
 
Table A6. Reagents and chemicals used during RNA precipitation. 
Reagent 
Supplier 
3 M NaAc pH 5.2  
0.1% DEPC H20 Sigma Life Science 
Ethanol Arcus kjemi, Norway 
ddH20 MilliQ Biocel, USA 
 
  
Table A7. Reagents and chemicals used when assessing RNA quality (Agilent 2100 Bio analyzer) 
Product Supplier 
Rnase zap Sigma, USA 
Rnase free ddH2O MilliQ Biocel Apparatus, USA 
RNA 6000 Nano LabChip Kit Agilent Technologies, USA 
RNA 6000 Nano Ladder Ambion, USA 
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Figure A1. RIN-numbers of 12 random samples obtained from bioanalyser. 
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Table A8. Reagents and chemicals used during reverse transcriptase reaction. 
Reagents Volume per sample (µl) Supplier 
ddH20 2,8 MiliQ Biocel, USA 
Forward primer (50µM) 0,1 Invitrogen, UK 
Backward primer (50µM) 0,1 Invitrogen, UK 
SYBR GREEN mastermix 5 Roche, Norway 
  
 
Table A9. List of primers used in Real-time PCR. 
Gene Forward primer (5' primer) Reverse primer (3' 
Tbp ACCCTTCACCAATGACTCCTATG ATGATGACTGCAGCAAATCGC 
Cd68 CTTCCCACAGGCAGCACAG AATGATGAGAGGCAGCAAGAGG 
F4/80 CTTTGGCTATGGGCTTCCAGTC GCAAGGAGGACAGAGTTTATCGTG 
Fas CTTCGCCAACTCTACCATGG TTCCACACCCATGAGCGAGT 
Ccl1 GTGTTGGCTCAGCCAGATGC GCTTGGTGACAAAAACTA 
Pck1 CCACACCATTGCAATTATGC CATATTTCTTCAGCTTGCGG 
Ppargc1a CATTTGATGCACTGACAGATGGA CCGTCAGGCATGGAGGAA 
Ppara CGTTTGTGGCTGGTCAAGTT AGAGAGGACAGATGGGGCTC 
Pparg ACAGCAAATCTCTGTTTTATGC TGCTGGAGAAATCAACTGTGG 
Srebf1 GGA GCC ATG GAT TGC ACA TT GCT TCC AGA GAG GAG CCC AG 
Tnf α CCCTCACACTCAGATCATCTT GCTACGACGTGGGCTACAG 
Pai AGCGGGACCTAGAGCTGGTC CCAGTAAGTCACTGATCATACCTTTGGT 
Scd 1 GATGTTCCAGAGGAGGTACTACAAGC ATGAAGCACATCAGCAGGAGG  
Acc1 TGCTGCCCCATCCCCGGG TCGAACTCTCACTGACACG 
Foxo1 TTTCTAAGTGGCCTGCGAGTC CCCATCTCCCAGGTCATCC 
Gl6 CTT CAA GTG GAT TCT GTT TGG AGA TGA CGT TCA AAC ACC GG 
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IV. APPENDIX - HISTOLOGY 
 
Table A10. Reagents used during the process of staining 
Product  
Supplier 
4 % formaldehyd  Merck, Germany 
NaH2PO4 x H2O   Merck, Germany 
Na2HPO4 x H2O   Merck, Germany 
Zinc Formalin Fixative Sigma, USA 
Ethanol  Arcus, Norway 
Rectified Alcohol  Arcus, Norway 
Xylene  VWR International, USA 
Paraffin  Histovax, OneMed 
Hematoxylin  EMS 
Eosin  Sigma, USA 
Hoecsht 33258 Merck, Germany 
Entellan mounting medium (Xylene-
based) Merck, Germany 
Fluorescent mounting medium Sigma, USA 
 
 
Table A11. Tissue dehydration schedule. 
Reagent 
Time 
75 % Alcohol 45 min 
95 % Alcohol 2 x 45min 
100 % Alcohol 3 x 45 min 
Xylene 2 x 45 min 
Paraffin overnight 
Paraffin 2 x 15 min 
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Table A12. Time schedule used in hematoxilin/eosin staining of pancreatic tissue. 
Reagent Time  
Xylene 2 x 10 min 
100 % EtOH 2 x 10 min  
95 % EtOH 2 x 5 min 
75 % EtOH 5 min 
50 % EtOH 5 min 
ddH2O 5 min 
Hematoxylin 30 sec 
H2O 4 min 
Eosin  5 sec 
H2O 4 min 
ddH2O 1 min 
50 % EtOH 2 min 
75 % EtOH 2 min 
95 % EtOH 2 x 2 min 
100 % EtOH 2 x 5 min 
Xylene 2 x 5 min 
 
 
Table A13. Time schedule used in Hoechst 33258 staining of pancreatic tissue. 
Reagent 
Time  
Xylene 2 x 10 min 
100 % EtOH 2 x 10 min  
95 % EtOH 2 x 5 min 
80 % EtOH 5 min 
70% EtOH 5 min 
50 % EtOH 5 min 
ddH2O 5 min 
Hoechst 33258 10 min 
H2O 10 min 
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V. APPENDIX – HEPATIC GENE EXPRESSION 
 
H e p a t ic  g e n e  e x p re s s io n
0
1 0 0
2 0 0
3 0 0
4 0 0
A c o x 1
R
e
la
ti
v
e
 e
x
p
re
s
s
io
n
L F H F /H S
0 ,3
m g /k g
1
m g /k g
3
m g /k g
1 0
m g /k g
0
1 0
2 0
3 0
4 0
P p a r a
R
e
la
ti
v
e
 e
x
p
re
s
s
io
n
L F H F /H S
0 ,3
m g /k g
1
m g /k g
3
m g /k g
1 0
m g /k g
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
P p a r g c 1 a
R
e
la
ti
v
e
 e
x
p
re
s
s
io
n
L F H F /H S
0 ,3
m g /k g
1
m g /k g
3
m g /k g
1 0
m g /k g
A .
C . E .
B .
D .
0
1 0 0 0
2 0 0 0
3 0 0 0
4 0 0 0
S c d 1
R
e
la
ti
v
e
 e
x
p
re
s
s
io
n
L F H F /H S
0 ,3
m g /k g
1
m g /k g
3
m g /k g
1 0
m g /k g
0
5
1 0
1 5
S r e b f1
R
e
la
ti
v
e
 e
x
p
re
s
s
io
n
L F H F /H S
0 ,3
m g /k g
1
m g /k g
3
m g /k g
1 0
m g /k g
F a tty  a c id  o x id a tio n  a n d  g lu c o n e o g e n e s is
L ip o g e n e s is  a n d  h e p a to s te a to s is
L F
H F
0 ,3  m g /k g  M e H g
1  m g /k g  M e H g
3  m g /k g  M e H g
1 0  m g /k g  M e H g
 
Figure A2. The effect of methylmercury on expression of genes involved in metabolic regulation. 
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Figure A3. The effect of methylmercury on expression of inflammation and macrophage infiltration markers. 
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VI.  APPENDIX – ORGAN MASS 
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Figure A4. Organ masses (g). 
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VII.  APPENDIX – HISTOLOGICAL IMAGES 
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Figure A5. Histopathology examinations of pancreatic sections. 
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Figure A6. Histopathological assessments of pancreatic mouse tissue. 
 
